Pr ot oc ol : 1 5 6 -1 3 -2 1 0  
C o nfi de ntial - Pr o prietar y I nf or mati o n   Pr ot oc ol n u m ber: 1 5 6- 1 3 -2 1 0 .  
  D oc u me nt title: A P hase 3 b, M ulti-ce nter, Ra n d o mize d- wit h dra wal, 
Place b o-c o ntr olle d , D o u ble- bli n d, Parallel- gr o u p Trial t o C o m pare t he 
Efficac y a n d Safet y of T ol va pta n ( 4 5 t o 1 2 0 m g/ da y, S plit- d ose) i n S u bjects 
wit h C hr o nic Ki d ne y Disease Bet wee n Late Sta ge 2 t o Earl y Sta ge 4 D ue t o 
A ut os o mal D o mi na nt P ol yc ystic Ki d ne y Disease 
  Versi o n n u m ber: 6. 
  D ate of t he d oc u me nt:  3 1 Mar 2 0 1 7. 
  N C T n u m ber: N C T 0 2 1 6 0 1 4 5. 
Ots u ka P har mace utica l De vel o p me nt & C o m mercializati o n, I nc.
I n vesti gati o nal Me dici nal Pr o d uct
T ol va pta n ( O P C - 4 1 0 6 1)
Pr ot oc ol 1 5 6 - 1 3- 2 1 0
I ND N o. 7 2, 9 7 5
E u dra C T N o. 2 0 1 4 -0 0 0 2 2 6 - 3 8
A P hase 3 b, M ulti- ce nter, Ra n d o mize d -wit h dra wal, Place b o -c o ntr olle d, D o u ble -bli n d, 
Parallel -gr o u p Trial t o C o m pare t he Efficac y  a n d Safet y of T ol va pta n ( 4 5 t o 1 2 0 m g/ da y, 
S plit -d ose) i n S u bjects wit h C hr o nic Ki d ne y  Disease Bet wee n Late Sta ge 2 t o Earl y 
Sta ge 4 D ue t o A ut os o mal D o mi na nt P ol y c ystic Ki d ne y Disease
St atistic al A n al ysis Pl a n
Versi o n: 6
D ate: M arc h 3 1, 2 0 1 7
C O N FI D E N TI A L – P R O P RI E T A R Y I N F O R M A TI O N
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7T a bl e of C o nt e nt s
T a ble of C o nte nts ...........................................................................................2
List of A p pe n dices ..........................................................................................4
List of A b bre vi ati o ns a n d Defi niti o n of Ter ms ...........................................5
1 I ntr o d ucti o n ..........................................................................................6
2 St u d y O bjecti ves ................................ ...................................................6
2. 1 Pri mar y  O bjecti ves ..............................................................................................6
2. 2 Sec o n dar y  O bjecti ves..........................................................................................6
3 St u d y Desi g n ..........................................................................................6
4 S a m ple Size a n d P o wer J ustific ati o n ..................................................7
4. 1 Sa m ple Size Esti mati o n .......................................................................................7
4. 2 Bli n de d Sa m ple Size Re -esti mati o n ..................................................................1 0
5 P atie nt S a m ples a n d H a n dli n g of Missi n g D at a ..............................1 1
5. 1 Patie nt Sa m ples .................................................................................................1 1
5. 2 A nal ys is Data Sets .............................................................................................1 1
5. 3  Ha n dli n g of Missi n g Data................................ .................................................1 2
6 St u d y C o n d uct .....................................................................................1 2
6. 1 Ra n d o mizati o n ...................................................................................................1 2
6. 2 Treat me nt C o m plia nce ......................................................................................1 2
7 B aseli ne C h ar acteristics .....................................................................1 3
8 Effic ac y A n al ysis .................................................................................1 3
8. 1 Pri mar y  O utc o me A nalys is ...............................................................................1 3
8. 1. 1 Pri mar y  E n d p oi nt A nalys is.............................................................................1 3
8. 1. 2 Se nsiti vit y  A nal ys is of t he Pri mar y E n d p oi nt ................................................1 5
8. 1. 3 Se nsiti vit y  A nalys is I ncl u di n g Data fr o m S u bjects W h o Disc o nti n ue 
I M P .................................................................................................................1 5
8. 2 Sec o n dar y  O utc o me A nal y sis ...........................................................................1 6
8. 2. 1 K e y  Sec o n dar y E n d p oi nt A nal ysis .................................................................1 6
8. 2. 2 Se nsiti vit y  A nalys is of t he Ke y Sec o n dar y E n d p oi nt.....................................1 6
8. 2. 3 Se nsiti vit y  A nalys is I ncl u di n g Data fr o m S u bjects W h o Disc o nti n ue 
I M P .................................................................................................................1 7
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 78. 2. 4 Se nsiti vit y  A nalys is I ncl u di n g I m p utati o n of Missi n g Data........................... 1 7
8. 3 Tec h nical C o m p utati o nal Details f or Pri mar y  a n d Sec o n dar y A nalys is...........1 9
8. 4 S u b gr o u p Efficac y  A nal ysis ..............................................................................2 7
8. 5 E x pl orat or y  A nalys is.........................................................................................2 7
9 S afet y A n al ysis ................................ ....................................................2 8
9. 1 A d verse E ve nts ................................ ..................................................................2 8
9. 2 Cli nic al La b orat or y Data...................................................................................2 8
9. 3 P h y sical E xa mi nati o n, a n d Vital Si g ns Data .....................................................2 9
1 0 I nteri m A n al ysis..................................................................................2 9
1 1 Refer e nce .............................................................................................3 0
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7Li st of A p p e n di c e s
A p pe n di x 1 Criteria of P ote ntiall y  Cli nicall y  Si g nifica nt La b orat or y Test 
A b n or malities ( M o difie d N CI  Criteria).........................................3 1
A p pe n di x 2 Criteria of P ote ntiall y  Clinicall y  Si g nifica nt Vital 
Si g n A b n or malities ................................ ........................................3 3
A p pe n di x 3 Ta ble of C o nte nts f or Cli nical Ta bles ............................................3 4
A p pe n di x 4 Ta ble of C o nte nts f or Cli nical Fi g ures ...........................................4 4
A p pe n di x 5 Bi ostatistics Me m ora n d u m o n Sa m ple Size Re -calc ulati o n ..........4 7
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 5 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7Li st of A b br e vi ati o n s a n d D efi niti o n of T er m s
A b bre vi ati o n Defi niti o n
A D P K D A ut os o mal d o mi na nt p ol yc ys tic k i d ne y disease
A E A d verse e ve nt
A L P Al kali ne p h os p hatase
A L T Ala ni ne a mi n otra nsferase
A N C O V A a nal ys is of c o varia nce
A N O V A a nal ys is of varia nce
A S T As partate a mi n otra nsferase
b p m beats per mi n ute
C K D C hr o nic k i d ne y disease
C R F Case re p ort f or m
e G F R Esti mate d gl o mer ular filtrati o n rate 
E u dra C T E ur o pea n Cli nical Trial Data Base
I M P I n vesti gati o nal me dici nal pr o d uct
I T T i nte nt-t o-treat
L L N l o wer li mit of n or mal
L O E Lac k of efficac y
M A R M issi n g at ra n d o m
Me d D R A Me dical Dicti o nar y  f or Re g ulat or y Acti vities
M M R M Mi xe d M o del Re peate d Meas ure me nts
M N A R M issi n g n ot at ra n d o m
S A P Statistical A nal y sis Pla n
S D sta n dar d de viati o n
T E A E Treat me nt -e mer ge nt a d verse e ve nt
U L N U p per li mit of n or mal
U S U nite d States
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 6 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 71 I ntr o d u cti o n
T his Statistical A nal y sis Pla n ( S A P) descri bes t he statistical met h o d ol o g y a n d data 
a nal ys is al g orit h ms a n d c o n ve nti o ns t o be a p plie d f or statistical a nalys is a n d re p orti n g of 
efficac y a n d safet y data of trial 1 5 6 - 1 3- 2 1 0.  
2 St u d y  O bj e cti v e s 
2. 1 Pri m ar y O bj e cti v e s
T he pri mar y o bjecti ves of t his trial are:
T o c o m pare t he efficac y  of t ol va pta n treat me nt i n re d uci n g t he c ha n ge i n esti mate d 
gl o mer ular filtrati o n rate (e G F R ) fr o m pre-treat me nt baseli ne t o p ost-treat me nt f oll o w-
u p, as c o m pare d wit h place b o, i n s u bjects wit h late -sta ge c hr o nic ki d ne y disease (C K D )
d ue t o A ut os o mal D o mi na nt P ol y c ystic Ki d ne y Disease (A D P K D ) w h o t olerate t ol va pta n 
d uri n g a n i nitial r u n- i n peri o d.
2. 2 S e c o n d ar y  Obj e cti v e s
T he sec o n dar y  o bjecti ves of t his trial are:
 T o c o m pare t he efficac y  of t ol va pta n treat me nt i n re d uci n g t he decli ne of an n ualize d 
e G F R sl o pe, as c o m pare d wit h place b o, i n s u bjects wit h late -sta ge C K D d ue t o
A D P K D w h o t olerate t ol va pta n d uri n g a n i nitial r u n- i n peri o d.
  T o c o m pare o verall a n d he p atic safet y of t ol va pta n wit h t hat of place b o a n d t o 
c o m pare i nci de nce of A D P K D c o m plicati o ns ( o utc o mes) d uri n g t he trial .
3 St u d y  D e si g n 
T his is a p hase 3, m ulti- ce nter, ra n d o mize d -wit h dra wal, place b o -c o ntr olle d, d o u ble -bli n d, 
parallel -gr o u p trial t o c o m pare t he efficac y  a n d safet y of t ol va pta n wit h place b o i n 
s u bjects wit h A D P K D a n d baseli ne ki d ne y f u ncti o n as d oc u me nte d by a n e G F R bet wee n
2 5 t o 6 5 m L / mi n/ 1. 7 3 m 2, i ncl usi ve.  T he o verall desi g n is ill ustrate d i n t he f oll o wi n g 
fi g ure.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 7 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 74 S a m pl e Si z e a n d P o w er J u stifi c ati o n
4. 1 S a m pl e Si z e E sti m ati o n
I n t his sa m ple size esti mati o n, it is ass u me d t hat 3 o bser vati o ns of e G F R are o bser ve d at 
baseli ne d uri n g a 3- wee k i nter val d uri n g scree ni n g ( 2 wee ks) a n d place b o r u n -i n 
( 1 wee k)a n d a gai n 3 o bser vati o ns are o bser ve d after o ne wee k p ost- treat me nt f oll o w- u p 
d uri n g a t w o wee k i nter val ( o ver a t otal of 3 wee ks).  T he mea n of t he 3 e G F R o bser ve d 
d uri n g t he scree ni n g a n d place b o -r u n peri o ds is set as t he baseli ne a n d t he mea n of t he 
3 e G F R o bser ve d d uri n g p ost- treat me nt f oll o w-u p peri o d is set as t he re nal f u ncti o n 
meas ure me nt p ost -treat me nt.  T he ti mi n g of baseli ne a n d p ost-treat me nt o bser vati o ns are 
set t o t he me dia n of t he o bser vati o n ti mes i n t he t w o-wee k i nter val res pecti vel y .  T h us, 
t he pre-treat me nt baseli ne will be set at a p pr o xi matel y 6 wee ks pri or t o ra n d o mizati o n, 
a n d t he p ost-treat me nt re nal f u ncti o n meas ure me nt will be set at a p pr o xi matel y 2 wee ks 
after t he e n d of treat me nt .
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 8 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7Base d o n a Mi xe d M o del Re peate d Meas ure me nts (M M R M ) a nal ys is of t he n o n-Ja pa n 
C K D -3 S u bjects fr o m trial , t he treat me nt differe nce i n re nal f u ncti o n at 
M o nt h 1 2 base d o n t he p ost -ra n d o mizati o n baseli ne is  
 
 
 
 
 we ma y ass u me t he treat me nt differe nce i n re nal f u ncti o n is 
1. 0 7 m L / mi n/ 1. 7 3 m 2 i n o ur sa m ple size calc ulati o n.  A n n ual re d ucti o n of G F R decli ne 
i n t he a m o u nt of 1. 0 7 m L/ mi n/ 1. 7 3 m 2 is cli nicall y mea ni n gf ul i n t he A D P K D patie nt 
p o p ulati o n st u die d i n t his pr ot oc ol (e G F R bet wee n 2 5 t o 6 5 m L / mi n/ 1. 7 3 m 2),   
 
 
T o i n vesti gate t he re d ucti o n i n i ntra- s u bject variati o n ac hie ve d by t a ki n g t he mea n of a n 
i ncrease d n u m ber of o bser vati o ns at baseli ne a n d p ost-treat me nt f oll o w-u p i n t he sa m ple 
size, we ha ve t o esti mate t he i ntra-s u bject err or a n d i nter -s u bject err or.
O ne of t he a p pr oac hes i n sa m ple size calc ulati o n f or t his pr ot oc ol is t o use M M R M t o 
esti mate t he i ntra- a n d i nter-s u bject varia nces.  I n t he A D P K D p hase 3 trial 1 5 6- 0 4- 2 5 1, 
t here were a pre-treat me nt baseli ne visit a n d t w o p ost -treat me nt f oll o w-u p visits, al o n g 
wit h s o me ot her o n -treat me nt visits.  Ass u me t hese data f oll o w t he f oll o wi n g m o del 
( de n ote d as j = 0 f or baseli ne a n d j = 3 7 f or f oll o w- u p, as well as j = 4, 8, 1 2, …, 3 6):
Yi, 0= αi+ εi, 0 ( 1)
Yi,j= αi+ δi,j+ εi,j ( 2)
w here δ i,j, as a ra n d o m effect of c ha n ge fr o m pre -treat me nt baseli ne f or s u bject i at visit j.  
T hese δ i,js are j oi ntl y f oll o w a m ulti variate n or mal distri b uti o n wit h mea ns bei n g δ P,jf or 
place b o s u bjects a n d δ T,jf or t ol va pta n s u bjects.  T heir i n di vi d ual varia nce is ass u me d 
bei n g   δ,j2.  T hese δ i,js are s u p p ose d t o be c orrelate d; h o we ver, t heir c orrelati o ns are n ot 
i ntereste d f or t he p ur p ose of sa m ple size calc ulati o n i n t his pr ot oc ol.  In a d diti o n, α is are 
ass u me d ii d n or mal distri b ute d, ε i,jare ass u me d ii d N( 0,  2), a n d t hese ra n d o m varia bles 
are m ut uall y i n de pe n de nt.  T he n, t he c ha n ge fr o m baseli ne data f oll o ws t his c o m m o nl y 
use d M M R M m o del:
Yi,j- Yi, 0= δi,j- εi, 0+ εi,j = ζi,j+ εi,j ( 3)
w here ζ i,j= δi,j- εi, 0.  N ote t hat t he varia nce of ζ i,j( de n ote d by   ζ,j2) is e q ual t o   δ,j2+  2.  
T his m o del bec o mes o ne -w a y  ra n d o m effect m o del if we o nly c o nsi der t he p ost -treat me nt 
f oll o w-u p visits f or a treat me nt gr o u p.  T h us, a p pl yi n g o ne -w a y  ra n d o m effect m o del t o 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 9 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7t he c ha n ge fr o m pre-treat me nt baseli ne t o p ost-treat me nt f oll o w-u p data of place b o a n d 
t ol va pta n res pecti vel y, i n s u bjects w h o ha d b ot h f oll o w- u p visits a n d baseli ne i n 
,  2is esti mate d as .  Ta ke t he a vera ge 
of t hese t w o esti mates of  2t o o btai n a n esti mate of  2as  t o be use d i n t his sa m ple 
size calc ulati o n, w hic h is t he    .  N ote t hat 
V ar( Y i,j- Yi, 0) =   δ,j2+ 2  2 ( 4)
At M o nt h 1 2, t he s ta ndar d d e viati o n ( S D)c o ul d be ass u me d as  
.  T he n base d o n ( 4),  δ,j2at M o nt h 1 2 is esti mate d as 
2 8. 0 5 . 
Wit h k re peate d meas ure me nts at pre- treat me nt baseli ne a n d at 1 2 m o nt h p ost-treat me nt 
f oll o w- u p i n t his trial, t he baseli ne i ntra-s u bject varia nce a n d t he f oll o w-u p i ntra -s u bject 
varia nce are re d uce d fr o m  2t o  2/ k res pecti vel y.  T h us, t he varia nce of avera ge c ha n ge 
fr o m a vera ge baseli ne at M o nt h 1 2 is (  δ, 1 22+  2/ k) +   2/ k, w hic h is esti mate d as 3 1. 6 
 w he n k = 4 a n d 3 2. 8  w he n k = 3.  Here 
we ha ve t he f oll o wi n g ta ble of sa m ple size: 
T ot al S a m ple Size wit h Δ = 1. 0 7 a n d 1 0 % Dr o p o ut R ate ( Al p h a = 0. 0 5)
# of Bl o o d Dra ws 1 2 3 4
9 0 % P o w er 1 7 2 2 1 4 3 4 1 3 3 6 1 2 8 8
8 5 % P o w er 1 4 7 7 1 2 3 0 1 1 4 6 1 1 0 6
8 0 % P o w er 1 2 8 6 1 0 7 0 9 9 8 9 6 2
Fr o m t he sa m ple size ta ble, t he i ncrease of re peate d meas ure me nt at baseli ne a n d f oll o w-
u p re d uces t he sa m ple size si g nifica ntl y  i nitiall y b ut q uic kl y l oses its effect w he n k is 
greater t ha n 3.  It see ms t hat 3 re peate d meas ure me nts ma y  be a p pr o priate i n or der t o 
a v oi d patie nts’ b ur de n.  T h us, wit h a n ass u m pti o n of 1 0 % dr o p o ut rate i n t he trial, t he 
t otal sa m ple size (ra n d o mize d s u bjects) w o ul d be a p pr o xi matel y 1 3 0 0.
T he desire f or a s mall n u m ber of bl o o d dra ws d uri n g t hese peri o ds was e m p hasize d b y  
t he trial’s Steeri n g Co m mittee w h o f urt her s u g geste d t hat meas ures be ta ke n t o mi ni mize 
t he i ntra-s u bject varia bilit y b y sta n dar dizi n g, as m uc h as p ossi ble, t he ti mi n g a n d 
c o n diti o ns b y w hic h ser u m creati ni ne was assesse d (i n partic ular rec o m me n di n g a si milar 
diet, a v oi di n g variati o n i n c o o ke d or u nc o o ke d pr otei n i nta ke a n d e xercise patter n be use d 
d uri n g t hese peri o ds).  T he Steeri n g C o m mittee als o s u g geste d t hat t he i ntra -s u bject 
varia nce d uri n g t he pre -treat me nt a n d p ost-treat me nt peri o ds be m o nit ore d t hr o u g h o ut t he 
trial with a ma n dat or y  i ncrease i n ser u m creati ni ne sa m ple n u m ber (ie, fr o m a mi ni m u m 
of 3 t o a mi ni m u m of 4) or s u bject n u m bers if o bser ve d varia nce was greater t ha n t hat 
use d i n t he p o wer ass u m pti o n (assesse d usi n g o nl y baseli ne e G F R data i n a p o wer re -
esti mati o n pr oce d ure).  T he y  als o fa v ore d t he p ossi bilit y t hat sa m ple n u m bers, b ut n ot t he 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 0 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7mi ni m u m e nr oll me nt, be l o were d (ie, t o a ma xi m u m of 3) if varia nce was si g nifica ntl y  
less d ue t o t hese meas ures.  ( See Secti o n 4. 2 “ Bli n de d Sa m ple Size Re -esti mati o n”).
F or t he sa m ple size of t he ke y sec o n dar y e n d p oi nt, l o n git u di nal a nalys is s pecifie d   
is a p plie d t o t he e G F R data of C K D- 3  s u bjects usi n g 
p ost -ra n d o mizati o n baseli ne, t o o btai n t he esti mates of t he varia nce of i nter-s u bject 
e G F R C K D- E PI sl o pe  a n d t he varia nce of i ntra -s u bject e G F R 
o bser vati o ns  .  T he p o wer calc ulati o n usi n g t he sa m ple size 
f or m ula pr o vi de d by Lefa nte1ass u mes t he f oll o wi n g:  1) place b o s u bjects w o ul d ha ve a n 
e G F R decli ne of 4. 5 ml/ mi n/ 1. 7 3 m2per y ear; 2) t ol va pta n s u bjects w o ul d ha ve a n e G F R 
decli ne re d uce d 2 5 % c o m pare d t o place b o s u bjects; 3) treat me nt d urati o n is o ne y ear 
wit h m o nt hl y  o bser vati o ns i n e G F R.  I n a d diti o n, t he 1: 1 ra n d o mizati o n a n d t he al p ha 
( 0. 0 5, t w o-si de d) s pecifie d a b o ve i n t he sa m ple size of t he pri mar y e n d p oi nt are als o 
ass u me d i n t he sa m pl e size calc ulati o n.  It is t he n esti mate d t hat 7 3 4 s u bjects are re q uire d 
f or 9 0 % p o wer.  T h us, wit h a t otal sa m ple size of ar o u n d 1 3 0 0 , t he ke y sec o n dar y 
e n d p oi nt will ha ve m ore t ha n 9 0 % p o wer i n detecti n g a sl o pe differe nce i n t his trial.
4. 2 Bli n d e d S a m pl e S i z e R e-e sti m ati o n
 
.  T his is e x pecte d t o be c o n d ucte d 
bef ore t he a vaila bilit y  of a n y p ost 1 2-m o nt h off -treat me nt f oll ow- u p e G F R data use d f or 
t he pri mar y a nal ysis.  T he g oal of t his bli n de d sa m ple size re-esti mati o n is t o c hec k: 1) 
t he differe nces bet wee n t he o bser ve d varia nces a n d t he varia nces use d i n t he sa m ple size 
calc ulati o n; 2) w het her t he a p pr oac h of a vera gi n g t he 3 e G F R o bser vati o n s at pre-
treat me nt baseli ne a n d p ost-treat me nt f oll o w- u p has ac hie ve d t he g oal of re d uci n g t he 
varia nce t o t he le vel we pla n ne d.  Base d o n t hese fi n di n gs, t he ser u m creati ni ne sa m ple 
n u m ber a n d s u bject sa m ple size of t his trial ma y nee d t o be a dj uste d.  
T o deri ve t he varia nce a n d its c o m p o ne nts use d i n t he sa m ple size re -calc ulati o n, t he 
re peate d meas ure me nts at pre-treat me nt baseli ne will be a nalyz e d usi n g t he o ne -w a y  
ra n d o m effect m o del s pecifie d i n ( 1), t o deri ve d t he i ntra-s u bject varia nce use d i n t he 
sa m ple size calc ulati o n pr o vi de i n t he pre vi o us secti o n.  C o m paris o n of t his deri ve d i ntra -
s u bject varia nce wit h varia nce at o n-treat me nt visits is als o necessar y t o assess t he 
re d ucti o n of t he varia nce t hr o u g h re plicate d o bser vati o ns. I n a d diti o n, re vie w of t he 
varia nce at o n -treat me nt visits will als o pr o vi de s o me cl ues t o t he varia nce at t he 
u n o bser ve d p ost -treat me nt f oll o w-u p visits .  Detaile d acti o ns i n t he bli n de d sa m ple size 
re-esti mati o n was d oc u me nte d i n  
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 1 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 75 P ati e nt S a m pl e s a n d H a n dli n g of Mi s si n g D at a
5. 1 P ati e nt S a m pl e s
T he f oll o wi n g sa m ples ( p o p ulati o ns) are defi ne d f or t his trial:
Ra n d o mize d P o p ulati o n:  All s u bjects w h o were ra n d o mize d i n t his trial.
Ra n d o mize d Safet y  P o p ulati o n: All s u bjects w h o were ra n d o mize d i n t his trial a n d t o o k 
at least o ne d ose of in vesti gati o nal me dici nal pr o d uct (I M P) after ra n d o mizati o n.  T his is 
t he pri mar y safety p o p ulati o n.
Treate d Safet y P o p ulati o n: All s u bjects w h o t o o k at least o ne d ose of I M P d uri n g t he 
t ol va pta n titrati o n/r u n-i n peri o ds. T his is a sec o n dar y  safet y p o p ulati o n.
Efficac y  P o p ulati o ns :  
Pri mar y  E n d p oi nt Efficac y P o p ulati o n : All s u bjects w h o are i n t he Ra n d o mize d Sa m ple, 
t o o k at least o ne d ose of I M P after ra n d o mizati o n, a n d ha ve a baseli ne a n d at least o ne 
vali d p ost -treat me nt e val uati o n i n e G F R (ie, at least o ne wee k off -treat me nt).  T he 
pri mar y  e n d p oi nt’s baseli ne is defi ne d as t he a vera ge of u p t o 3 e G F R val ues o bser ve d 
d uri n g t he scree ni n g a n d place b o r u n -i n peri o ds.
K e y  Sec o n dar y E n d p oi nt Efficac y P o p ulati o n :  All s u bjects w h o are i n t he Ra n d o mize d 
Sa m ple, t o o k at least o ne d ose of I M P after ra n d o mizati o n, a n d ha ve a baseli ne a n d at 
least o ne p ost-ra n d o mizati o n e val uati o n i n e G F R d uri n g t he d o u ble -bli n d treat me nt 
peri o d .  T his is si milar t o t he Pri mar y E n d p oi nt Efficac y Sa m ple, e xce pt t hat p ost-
treat me nt e val uati o n i n e G F R is re place d by p ost -ra n d o mizati o n e val uati o n. T he baseli ne 
of t he ke y  sec o n dar y e n d p oi nt is i de ntical t o t he baseli ne of the pri mar y  e n d p oi nt.  
5. 2 A n al y si s D at a S et s
T he c ore patie nt p o p ulati o n f or all efficac y  a nalys es is base d o n t he i nte nt -t o-treat (I T T) 
p o p ulati o n w hic h c o nsist s of all ra n d o mize d s u bjects w h o ta ke at least o ne d ose of I M P
p ost -ra n d o mizati o n.  As will be descri be d bel o w, i n or der t o ha n dle missi n g a n d 
restricti o ns i m p ose d b y differe nt ty pes of a nal ys es (e g, c ha n ge fr o m baseli ne a nal ys is), 
datasets base d o n m o difie d I T T p o p ulati o n will be use d i n t he efficac y  a nal yses.
T he O bser ve d Cases ( O C) dataset of t his p r ot oc ol is defi ne d as t he data o bser ve d at st u d y 
s pecifie d visits.  F or t he pri mar y o utc o me varia ble of t his pr ot oc ol, t he O C dataset 
c o nsists of t he pre-treat me nt baseli ne (a vera ge of e G F R o bser ve d i n scree ni n g peri o d a n d 
t he first e G F R o bser ve d i n place bo r u n -i n peri o d) a n d p ost-treat me nt f oll o w-u p (a vera ge 
of e G F R o bser ve d i n a t w o -wee k i nter val w hic h is o ne wee k p ost t he last I M P d ose).  F or 
t he ke y sec o n dar y o utc o me varia ble of t his pr ot oc ol, t he O C dataset wit hi n treat me nt 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 2 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7peri o d is defi ne d as t he dat a o bser ve d at st u d y s pecifie d visits w hile s u bjects are ta ki n g 
I M P or wit hi n 2 4 h o urs of t he last I M P d ose .  
5. 3 H a n dli n g of Mi s si n g D at a
T he G F R esti mate d b y t he C K D -E PI f or m ula is utilize d as t he pri mar y  efficac y 
assess me nt i n t his trial.  
I n t his pr ot oc ol, all data c ollecte d f or t he pre-treat me nt baseli ne a n d p ost-treat me nt 
f oll o w-u p peri o ds descri be d i n Secti o n 5. 2 will be use d a n d missi n g data will n ot be 
i m p ute d i n deri vi n g t he pre-treat me nt a n d p ost-treat me nt e G F R o bser vati o ns use d f or t he 
pri mar y  a nalys is.
F or se nsiti vit y  a nalys es of t he pri mar y a nal ysis, i n ge neral, missi n g data will be ha n dle d 
b y  a nalys is usi n g mi xe d m o del met h o d ol o g y u n der t he ass u m pti o n of “ missi n g at 
ra n d o m” ( M A R).  H o we ver, t he p ossi bilit y of “ missi n g n ot at ra n d o m” ( M N A R) data ca n 
ne ver be r ule d o ut.  T h us, e ver y  eff ort will be ma de t o f oll o w t he s u bjects w h o 
disc o nti n ue i n vesti gati o nal t hera p y after ra n d o mizati o n wit h o ut wit h dra wi n g c o nse nt f or 
f oll o w-u p of t heir e G F R assess me nts.  W he n c ollecte d wit hi n t he last t w o wee ks of t he 
3 wee ks i m me diatel y p ost I M P wit h dra wal, t he dat a will be i ncl u de d i n t he pri mar y 
a nal ys is.  Ot her wise, e G F R assess me nts c ollecte d d uri n g or after t his peri o d will be 
i ncl u de d i n se nsiti vit y a nal ysis.  A d diti o nal se nsiti vit y a nalys is will be c o n d ucte d f or t he 
ke y  sec o n dar y e n d p oi nt f or all s u bjects w h o wit h dra w c o nse nt or w h o are l ost t o f oll o w 
u p, usi n g m ulti ple i m p utati o n met h o d ol o g y  u n der a p pr o priate ass u m pti o ns.  See 
Secti o n 8. 2. 4 f or m ore details.
6 St u d y  C o n d u ct
6. 1 R a n d o mi z ati o n
Ce ntral ra n d o mizati o n will be perf or me d t hr o u g h I V R S t o ra n d o mize s u bjects t o 
treat me nt gr o u p i n 1: 1 rati o, stratifie d b y baseli ne G F R le vel  
, a ge ( ≤ 5 5 y ears or n ot) a n d T otal Ki d ne y V ol u me 
( .
6. 2 Tr e at m e nt C o m pli a n c e
Base d o n t he St u d y  Me dicati o n pa nel of t he case re p ort f or m (C R F ), c o m plia nce i n 
ta ki n g t ol va pta n is calc ulate d b y di vi di n g t he t otal d osa ge ta ke n by t he t otal d osa ge t he 
patie nts were sc he d ule d t o ta ke d uri n g t he st u d y peri o d.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 3 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 77 B a s eli n e C h ar a ct eri sti c s
De m o gra p hic c haracteristics i ncl u di n g a ge, race, et h nicit y , ge n der, wei g ht, hei g ht a n d 
b o d y  mass i n de x (B MI ) will be s u m marize d b y  descri pti ve statistics, e g, pr o p orti o n, 
mea n, me dia n, S D, mi ni m u m a n d ma xi m u m val ues. 
8 Effi c a c y A n al y s i s
8. 1 Pri m ar y  O ut c o m e A n al y si s
T h is trial’s esti ma n d is t he differe nce i n o utc o me i m pr o ve me nt if all s u bjects t olerate d 
a n d a d here d t o t heir treat me nt.  T o e nric h t his p o p ulati o n, o nl y  s u bjects t hat ca n t olerate 
t he t ol va pta n titrati o n a n d r u n-i n peri o ds will be ra n d o mize d.  T his a p pr oac h c o m bi nes 
esti ma n ds # 2 a n d # 3 rec o m me n de d b y  t he 2 0 1 0 Nati o nal Aca de m y of Scie nces’ Nati o nal 
Researc h C o u ncil re p ort o n pre ve nti o n a n d treat me nt of missi n g data.2  T h us, data M A R 
is ass u me d i n t he pri mar y a nal ysis.  Se nsiti vit y a nal ysis will be pr o vi de d t o a d dress t he 
c o ncer n of data M N A R.
T his esti ma n d f oc uses o n t he efficac y  of t ol va pta n i n sl o wi n g re nal f u ncti o n decli ne.  T he 
o bjecti ve of t his trial is t o c o nfir m a ca usal effect of t ol va pta n i n sl o wi n g re na l f u ncti o n 
decli ne, c o nsiste nt wit h t he selecti o n of a n efficac y rat her t ha n effecti ve ness esti ma n d. 
A n effecti ve ness esti ma n d c o m pares treat me nt p olicies a n d reas o na bl y c o ul d i ncl u de data 
ac q uire d l o n g after wit h dra wal fr o m t he trial (e g, w he n s u bjects d isc o nti n ue t ol va pta n b ut 
are f oll o we d f or ma n y wee ks or m o nt hs) or m o ve t o a n alter nate treat me nt re gi me n 
(e g, place b o s u bjects bei n g prescri be d c o m mercial t ol va pta n u p o n a p pr o val f or A D P K D).  
I n t he a bse nce of a n a p pr o ve d a n d effecti ve alter nate treat me nt f or A D P K D; it is 
pre mat ure t o disc uss treat me nt p olicies.  T h us, w hile e G F R data c ollecte d i n t he sec o n d 
a n d t hir d wee k p ost wit h dra wal are use d f or a nal ysis of t he pri mar y  e n d p oi nt, data 
c ollecte d l o n g after wit h dra wal or after a s u bject m o ves t o a n alter nate treat me nt re gi me n 
will be e xcl u de d i n t he pri mar y  a nalys es of b ot h t he pri mar y  a n d t he ke y sec o n dar y 
e n d p oi nts.
Pr o p ose d ta bles a n d fi g ures t o be ge nerate d f or t he efficac y  a nalys is ca n be f o u n d i n 
A p pe n di x 3 a n d A p pe n di x 4 .
8. 1. 1 Pri m ar y  E n d p oi nt A n al y si s
A t w o -si de d al p ha of 0. 0 5 will be a p plie d t o t he pri mar y a nalys is of t he pri mar y e n d p oi nt.
T he pri mar y  e n d p oi nt of t his trial is c ha n ge i n e G F R ( C K D-E PI ) fr o m pre-treat me nt 
baseli ne t o p ost -treat me nt f oll o w-u p, a n n ualize d ( di vi de d) b y  s u bjects’ trial d urati o n.  
T his n or malizati o n is necessar y , ot her wise t he treat me nt gr o u p ha vi n g m ore dr o p o uts or 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 4 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7m ore earlier dr o p o uts ma y ass u me a n u nfair a d va nta ge.  H o we ver, i n or der t o re d uce t he 
i m pact of t he o utliers create d by t he a n n ualize d e G F R c ha n ge i n earl y dr o p o ut s u bjects, 
all a n n ualize d c ha n ges of dr o p o ut s u bjects t hat are greater ( or less) t ha n t he ma xi m u m ( or 
mi ni m u m) of t he a n n ualize d e G F R c ha n ge of all o n- treat me nt c o m pleters will ass u me t he 
ma xi m u m ( or mi ni m u m) val ue as t heir a n n ualize d e G F R c ha n ges use d i n t he pri mar y  
a nal ys is.  T his is beca use of t he p ossi bilit y t hat a n n ualizati o n of ver y varia ble s h ort-ter m 
data ( o ne or t w o m o nt hs) b y  re q uiri n g a m ulti plicati o n fact or of 1 2 or 6 ca n res ult i n a n 
e xa g gerate d esti mate of a n n ualize d e G F R c ha n ge.  Earl y e xa m ples s h o we d t hat t his 
ca n n ot be a de q uatel y ma na ge d b y si m ple wei g hti n g i n t he a nal ys is.  T heref ore, 
restricti o ns o n t he ma xi m u m a n d mi ni m u m val ues o bser ve d i n t he o n-treat me nt 
c o m pleter p o p ulati o n ca n f urt her b uffer t he u nt o war d effects of s uc h o utliers.  I n 
a d diti o n, t he a nal ys is base d o n t he u na dj uste d a n n ualize d e G F R c ha n ges will ser ve as a 
se nsiti vit y a nalys is of t he pri mar y e n d p oi nt.  T o re d uce t he va riati o n i n t his pri mar y 
e n d p oi nt, t he last 3 o bser vati o ns of e G F R u p t o place b o r u n -i n are o bser ve d at baseli ne  
(scree ni n g a n d place b o r u n-i n peri o ds) a n d a n ot her first 3  o bser vati o ns are o bser ve d after 
o ne wee k of p ost -treat me nt f oll o w-u p d uri n g a t w o w ee k i nter val ( wit hi n a t otal of 
3 -wee ks p ost -treat me nt f oll o w-u p).  Alt h o u g h it was i nitiall y  desi g ne d t o ha ve s u bjects 
ca me bac k i n t his t w o wee k peri o d t o ha ve t heir e G F R meas ures, it t ur ns o ut t hat n ot all 
s u bjects c o ul d ac hie ve t his i n o ur cli nical o perati o n.  In or der t o re d uce e xcl u di n g 
s u bjects i n t he pri mar y a nal ysis d ue t o faili n g t o ha ve f oll o w-u p data wit hi n t his t w o 
wee k peri o d, t he wi n d o w t o ha ve f oll o w- u p e G F R o bser vati o ns is t h us set t o be fr o m 7 t o 
4 0 da y s p ost t he last d ose of I M P.  Beca use t he pri mar y e n d p oi nt is a n n ualize d e G F R 
c ha n ge, e xte n di n g t he f oll o w -u p wi n d o w d oes n ot c ha n ge place b o s u bjects’ pri mar y  
e n d p oi nt, si nce t he d urati o n fr o m baseli ne t o f oll o w -u p w o ul d be e xte n de d as well.  F or 
t ol va pta n s u bjects, t his wi n d o w defi niti o n is act uall y c o nser vati ve, si nce a fe w da ys of n o 
treat me nt w o ul d be a d de d t o t he d urati o n of t ol va pta n treat me nt f or t he a n n ualizati o n.  
T he a vera ge of t he 3 e G F R val ues o bser ve d d uri n g t he baseli ne peri o d is set as t he 
baseli ne a n d t he a vera ge of t he 3 e G F R val ues o bser ve d d uri n g p ost -treat me nt f oll o w- u p 
peri o d is set as t he re nal f u ncti o n meas ure me nt p ost- treat me nt.  T he dates of baseli ne a n d 
p ost -treat me nt o bser vati o ns are als o set t o t he me dia n of t he dates of t he ( u p t o) t hree 
baseli ne a n d t he ( u p t o) t hr ee p ost-treat me nt f oll o w-u p o bser vati o ns res pecti vel y , a n d t he 
d urati o n is e q ual t o t he date of p ost- treat me nt f oll o w- u p mi n us t he date of baseli ne pl us 
o ne.  T his d urati o n is use d i n t he calc ulati o n of t he a n n ualize d c ha n ge.  
Use of t he d urati o n t o a n n ualize t he c ha n ge is als o reas o na ble si nce it will pr o vi de a n 
“esti mate” of a n n ualize d e G F R c ha n ge sl o pe f or eac h s u bject, t h o u g h t here is n o esti mate 
f or i ntra-s u bject variati o n ass ociate d wit h it.  T h us, a wei g hte d a nal ys is of c o varia nce 
(A N C O V A ) wit h effe cts of treat me nt a n d ra n d o mizati o n stratificati o n fact ors a n d 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 5 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7c o variate baseli ne will be a p plie d t o t he a nal ys is of t hese “esti mate d sl o pes” as t he 
pri mar y  a nalys is.  T his wei g hte d a nalys is is base d o n t he reci pr ocal of t he esti mate d 
varia nce of t he “esti m ate d sl o pes”, a n d t he detaile d al g orit h m t o deri ve t he esti mate d 
varia nce will be pr o vi de d i n Secti o n 8. 3 f or C o m p utati o n Details of t he Pri mar y a n d 
Sec o n dar y  A nalys es.
8. 1. 2 S e n siti vit y A n al y si s of t h e Pri m ar y  E n d p oi nt
Ali g ne d wit h t he desire t o e val uate effects free fr o m ac ute he m o d y na mic treat me nt 
effects, a se nsiti vit y a nal ysis of t he pri mar y e n d p oi nt will be perf or me d i ncl u di n g all 
a vaila ble place b o data.  I n t his se nsiti vit y a nalys is, i n a d diti o n t o t he 3 pre-treat me nt 
baseli ne o bser vati o ns a n d t he 3 p ost -treat me nt f oll o w-u p o bser vati o ns, all p ost -
ra n d o mizati o n o n-treat me nt e G F R o bser vati o ns i n t he pr ot oc ol s pecifie d visits f or 
place b o s u bjects will als o be i ncl u de d.  T he li near mi xe d effect m o del wit h effects of 
treat me nt, ti me (as a c o nti n u o us varia ble), treat me nt ti me i nteracti o n, ra n d o mizati o n 
stratificati o n fact ors, a n d baseli ne as c o variate will be use d t o fit t he e G F R data , i n w hic h 
t he i nterce pt a n d ti me are b ot h a fi xe d effect a n d a ra n d o m effect.  A n u n- str uct ured
varia nce c o varia nce matri x is ass u me d f or t he ra n d o m i nterce pt a n d ti me.   T he ti me 
varia ble use d i n t he m o del ma y start fr o m t he first o bser vati o n of e G F R base li ne as 
me nti o ne d i n Secti o n 8. 1. 1 , a n d t his baseli ne will be use d i n t he m o del.  Missi n g data will 
be i g n ore d i n t his a nal y sis u nder M A R ass u m pti o n.  Data ac q uire d w hile ta ki n g assi g ne d 
t ol va pta n ca n n ot be use d i n t his a nal ysis wit h o ut a p pr o priate a dj ust me nt, b ut is e val uate d 
i n t he ke y sec o n dar y efficac y e n d p oi nt of e G F R sl o pe wit h a met h o d ol o g y w hic h ta kes 
t he ac ute he m o d yna mic dr u g effects of t ol va pta n i nt o acc o u nt.
8. 1. 3 S e n siti vit y A n al y si s I n cl u di n g D at a fr o m S u bj e ct s W h o 
Di s c o nti n u e I M P
T he se nsiti vit y  a nalys is de viates fr o m t he M A R ass u m pti o n t o i ncl u de t he p ost-
disc o nti n uati o n f oll o w -u p data i n t he a nal ys is s pecifie d i n t he secti on of t he pri mar y  
a nal ys is.  Su bjects w h o disc o nti n ue treat me nt after ra n d o mizati o n wit h o ut wit h dra wi n g 
c o nse nt will als o be f oll o we d f or a d diti o nal off-treat me nt e G F R val ues u p t o M o nt h 1 2.  
T hese p ost “ p ost -treat me nt f oll o w-u p” e G F R data at M o nt h 1 2 will be i ncl u de d t o re place 
t he data o bser ve d d uri n g p ost-treat me nt f oll o w-u p f or t he s u bjects w h o disc o nti n ue I M P 
earl y i n a se nsiti vit y a nal ysis usi n g t he sa me a nal ytic a p pr oac h s pecifie d i n t he secti o n of 
t he pri mar y a nal ysis.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 6 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 78. 2 S e c o n d ar y  O ut c o m e An al y si s
8. 2. 1 K e y  S e c o n d ar y  E n d p oi nt A n al y si s
T he a nal ys is of t he ke y sec o n dar y e n d p oi nt will be f or mall y c o n d ucte d, o nce t he pri mar y 
e n d p oi nt is si g nifica nt at a t w o -si de d al p ha of 0. 0 5.  T he n a t w o-si de d al p ha of 0. 0 5 will 
be a p plie d t o t he pri mar y a nal ys is of t he ke y seco n dar y  e n d p oi nt.
T he ke y  sec o n dar y e n d p oi nt of t he trial is t he a n n ualize d rate of e G F R c ha n ge, w hic h is 
deri ve d fr o m eac h i n di vi d ual s u bject’s e G F R sl o pe usi n g t he C K D -E PI f or m ula .  Sl o pe is 
preferre d as a practical a n d cli nicall y  mea ni n gf ul e n d p oi nt.  In t his a nal ysis, all e G F R 
o bser vati o ns fr o m place b o r u n- i n, t ol va pta n r u n-i n ( n ot i ncl u di n g t ol va pta n titrati o n), 
d o u ble -bli n d treat me nt, a n d p ost-treat me nt f oll o w- u p ( n ot i ncl u di n g data c ollecte d i n t he 
first wee k after t he last I M P d ose) peri o ds will be incl u de d i n t he a nal ys is, wit h t he data 
of t ol va pta n r u n -i n a n d t ol va pta n s u bjects i n t he d o u ble -bli n d treat me nt peri o d are 
fla g ge d ( yes = 1 a n d n o = 0) wit h a t ol va pta n ac ute he m o d y na mic effect.  T he li near 
mi xe d effect m o del wit h effects of ti me (as a c o n ti n u o us varia ble), treat me nt, ti me-
treat me nt i nteracti o n, ac ute he m o d yna mic effect, pre -treat me nt baseli ne ( of t he pri mar y 
e n d p oi nt), a n d ra n d o mizati o n stratificati o n fact ors will be use d t o fit t he G F R esti mates, 
i n w hic h t he i nterce pt a n d ti me are b ot h a fi xe d effect a n d a ra n d o m effect.  A n u n-
str uct ure d varia nce c o varia nce matri x is ass u me d f or t he ra n d o m i nterce pt a n d ti me.  T he 
ti me varia ble use d i n t he m o del ma y start fr o m t he first o bser vati o n of e G F R o btai ne d 
fr o m place b o r u n-i n peri o d.  T he c o vari ate “ac ute he m o d yna mic effect” i n t he m o del is 
t he fla g varia ble wit h val ue of 0 a n d 1 s pecifie d earlier i n t his secti o n f or t he data 
o bser ve d d uri n g t ol va pta n r u n -i n a n d t he data o bser ve d f or t ol va pta n s u bjects d uri n g t he 
d o u ble -bli n d treat me nt peri o d.  The starti n g p oi nt of t his e G F R sl o pe a nal ysis is t he 
e G F R o bser vati o n d uri n g t he place b o r u n -i n peri o d.
8. 2. 2 S e n siti vit y A n al y si s of t h e K e y  S e c o n d ar y E n d p oi nt
T his se nsiti vit y  a nalys is of t he ke y sec o n dar y e n d p oi nt of t his trial is t o c o m pare t he 
li near tre n d of e G F R bet wee n t ol va pta n a n d place b o gr o u ps.  T he a d va nta ge of t his 
se nsiti vit y a nalys is is t hat it d oes n ot de pe n d o n t he ass u m pti o n of li nearity a n d e q ual 
t ol va pta n he m o d yn a mic o nset a n d offset effects use d i n Secti o n 8. 2. 1 .  T he c ha n ge fr o m 
t he pre-treat me nt baseli ne d uri n g t he o n-treat me nt visits i n t he d o u ble -bli n d treat me nt 
peri o d will be i ncl u de d i n t he a nal ys is.  Si nce t he he m o d yna mic effects of t ol va pta n are 
belie ve d t o be gi n t o re verse wit hi n 1 t o 2 da y s, t heref ore o n-treat me nt will be defi ne d as 
wit hi n 2 4 h o urs of t he last I M P d ose.
A nal y sis of M M R M will be a p plie d t o t he data of c ha n ge fr o m baseli ne i n e G F R i n 
M o nt h 1, M o n t h 2, …, u p t o M o nt h 1 2.  T he m o del will ha ve fi xe d effect of treat me nt, 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 7 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7visit, treat me nt visit i nteracti o n, ra n d o mizati o n stratificati o n fact ors, a n d c o variate 
baseli ne a n d baseli ne visit i nteracti o n.  A n u nstr uct ure d varia nce -c o varia nce matri x is 
ass u me d f or t he re peate d meas ure me nts.  A li near c o ntrast of t he treat me nt differe nces i n 
t hese 1 2 m o nt hs will be use d as t he se nsiti vit y a nal ysis of t he ke y sec o n dar y e n d p oi nt.
A n ot her se nsiti vit y  a nal ysis will a p pl y M M R M a nal ysis si milar t o t he o ne pr o vi de d i n t he 
pre vi o us para gra p h ( wit h o ut deri vi n g li near c o ntrast) t o t he data of c ha n ge fr o m baseli ne 
i n e G F R, fr o m T ol va pta n Titrati o n Visit, T ol va pta n R u n-i n Visits 1 a n d 2, a n d M o nt h 1, 
M o nt h 2, ..., u p t o M o nt h 1 2, a n d P ost- treat me nt F oll o w-u p Visit (a vera ge).     
8. 2. 3 S e n siti vit y A n al y si s I n cl u di n g D at a fr o m S u bj e ct s W h o 
Di s c o nti n u e I M P
T his se nsiti vit y  a nalys is de viates fr o m t he M A R ass u m pti o n t o i ncl u de t he p ost-
disc o nti n uati o n f oll o w -u p data i n t he a nal ys is of t he ke y sec o n dar y e n d p oi nt.  Su bjects 
w h o disc o nti n u e treat me nt after ra n d o mizati o n wit h o ut wit h dra wi n g c o nse nt will be 
f oll o we d f or a d diti o nal e G F R ( n ot i ncl u di n g t he e G F R o bser ve d i n t he 3 wee k peri o d 
i m me diatel y p ost t he last d ose of I M P)  u p t o M o nt h 1 2.  T he data c ollecte d d uri n g t his 
f oll o w- u p peri o d will n ot be i ncl u de d i n t he k e y  sec o n dar y e n d p oi nt a nal ys is f or t he 
reas o ns gi ve n a b o ve.  H o we ver, a se nsiti vit y  a nal ysis i ncl u di n g t hese f oll o w-u p data f or 
t he ke y sec o n dar y a nalys is will be perf or me d.  T his a nal ysis uses t he sa me a p pr oac h 
pr o vi de d i n t he Secti o n 8. 2. 1 f or t he a nal ysis of t he ke y sec o n dar y e n d p oi nt.
8. 2. 4 S e n siti vit y A n al y si s I n cl u di n g I m p ut ati o n of Mi s si n g D at a
M ulti ple i m p utati o n is c o m m o nl y use d i n t he a nal ysis of M N A R data.  F or all 
ra n d o mize d s u bjects w h o wit h dra w earl y, i m p utati o n of missi n g data will be a p plie d t o 
pr ojecte d visits u p t o t heir pla n ne d e n d of t he trial ( 1 2 m o nt hs p ost -ra n d o mizati o n). T he
s u bjects’ reas o ns f or disc o nti n uati o n will be ca pt ure d a n d cate g orize d t o hel p deter mi ne 
t he missi n g data patter n .  I mp utati o n will be base d o n t he data use d i n t he M M R M m o del 
s pecifie d i n Secti o n 8. 2. 2 .  In or der t o perf or m t he a nal ys is of ra n d o m c oefficie nt 
re gressi o n m o del s pecifie d f or t he ke y sec o n dar y e n d p oi nt, si m ulate d val ue of a missi n g data 
will be assi g ne d a val ue f or t he ti me varia ble use d i n re gressi o n w hic h is e q ual t o t he ti me 
of its pre vi o us visit pl us 3 0. 5 da y s.  F or place b o s u bjects, a n d i n t he a bse nce of e vi de nce 
s u g gesti n g biase d missi n g data patter n, t he i m p utati o n will f oll o w t he place b o tre n d.  
 
 
 
 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 8 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7.  T he i m p utati o n of t hese 
t ol va pta n wit h dre w s u bjects is base d o n t he f oll o wi n g:
T hese i m p ute d data will be a d de d t o t he data descri be d i n Secti o n 8. 2. 1 a n d Secti o n 8. 2. 3
f or t w o sets of se nsiti vit y a nal yses.  I n eac h set of se nsiti vit y a nalys is, reas o n of 
disc o nti n uati o n will be classifie d i n t he f oll o wi n g or der as :
1) Pr o gressi o n of re nal disease 
2) Lac k of efficac y
3) Ot her A d verse E ve nt
4) A q uaretic A E ( Me d D R A preferre d ter ms of T HI R S T, P O L Y U RI A, N O C T U RI A, 
P O L L A KI U RI A, P O L Y DI P SI A)
5) Trial t o o b ur de ns o me
6) C o m mercial t ol va pta n f or A D P K D a vaila ble
T his lists reas o ns f or missi n g data d ue t o disc o nti n uati o n of trial partici pati o n i n a 
decreasi n g or der of t heir li keli h o o d t o pr o d uce data M N A R.  S pecificall y , M N A R i n t he 
f oll o wi n g patter ns of dr o p o ut reas o ns will be i n vesti gate d:
1. Pr o gressi o n of re nal disease a n d Lac k of efficac y  ( L O E) i n t ol va pta n treat me nt 
gr o u p as M N A R
2. Pr o gressi o n of re nal disease, L O E , a n d ot her a d verse e ve nts ( A E)  i n t ol va pta n 
treat me nt gr o u p as M N A R
  
 
 
 
  T heref ore, 
t he f oll o wi n g delta a dj ust me nt i m p utati o n met h o d will be a p plie d:  
Delt a A dj ust me nt I m p ut ati o n Met h o d
T his M N A R se nsiti vit y  a nal ysis is t o i n vesti gate t he de part ure fr o m M A R ass u m pti o n b y 
pr o gressi vel y decreasi n g t he treat me nt differe nces o ver t he missi n g visits i n t h ose treate d 
s u bjects w h o fell i nt o a n ass u me d M N A R patter n.  T his pr o gressi ve decrease of treat me nt 
sl o pe differe nce is carrie d o ut b y s u btracti n g k ti mes t he e x pecte d treat me nt differe nce (i n 
t he a bse nt of t he he m o d y na mic effect) fr o m t he i m p ute d missi n g data after dr o p o ut usi n g 
t ol va pta n sl o pe i n t h ose treate d s u bjects w h o fell i nt o a n ass u me d M N A R patter n, wit h k 
starts fr o m 0 %, 1 0 %, 2 0 %, .., a n d u p t o 1 0 0 % or hi g her, u ntil c o ncl usi o n fr o m t he 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 1 9 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7a nal ys is of t he ke y  sec o n dar y e n d p oi nt is o vert ur ne d (it is calle d ti p pi n g p oi nt a nal ysis), 
or it bec o mes cli nicall y mea ni n gless t o g o e ve n hi g her.  T he e x pecte d treat me nt 
differe nce bet wee n t ol va pta n a n d place b o at a visit m a y be deri ve d fr o m t he treat me nt 
differe nce i n sl o pe, m ulti plie d b y  t he visit m o nt h n u m ber a n d di vi de d b y 1 2.  N ote t hat 
w he n 0 % is use d, t he MI pr oce d ure w o ul d pr o d uce a n a nal ys is w hic h is esse ntiall y M A R.  
W he n 1 0 0 % is use d, t he MI  pr oce d ure w o ul d pr o d uce a n a nal ys is w hic h is esse ntiall y 
s o met hi n g calle d “c o py place b o”.  S pecificall y t he MI  pr oce d ure f oll o ws t hese ste ps: 
 Usi n g M o nte Carl o Mar k o v C hai n ( M C M C) met h o d ol o g y  fr o m P R O C MI b y 
treat me nt gr o u p t o i m p ute t he i nter mitte nt missi n g data t o a m o n ot o ne missi n g 
patter n;
 Usi n g a sta n dar d M A R -base d m ulti ple i m p utati o n a p pr oac h fr o m P R O C MI t o 
i m p ute data fr o m m o n ot o ne missi n g data;
 F or s u bjects i n t he treate d gr o u ps w h o fall i nt o a M N A R patter n s pecifie d a b o ve, 
a delta w hic h e q ual t o k ti mes t heir treat me n t differe nces me nti o ne d a b o ve will be 
s u btracte d f or t heir i m p ute d val ues after t he dr o p o ut ti me , wit h k descri be d i n t he 
a b o ve para gra p h;
 Usi n g t he ra n d o m c oefficie nt re gressi o n m o del s pecifie d i n t he pre vi o us secti o n t o 
a nal yz e d t he c o m plete d data al o n g wit h t he i m p ute d data;
 O btai ni n g t he o verall res ults usi n g P R O C MI A N A L Y Z E.
8. 3 T e c h ni c al C o m p ut ati o n al D et ail s f or Pri m ar y  a n d S e c o n d ar y 
A n al y si s
( 1) T w o sa m ples/ali q u ots of bl o o d will be c ollecte d f or ser u m creati ni ne as sess me nts.  
W hile o ne bl o o d sa m ple will be a nalyz e d b y t he ce ntral la b orat or y  as s o o n as it is 
recei ve d a n d accessi o ne d, t he ot her o ne will be fr oze n a n d later batc he d a nal ysis w he n a 
s u bject c o m pletes all his/ her ser u m creati ni ne bl o o d dra ws nee de d i n t he pr ot oc ol.  T his 
batc he d assess me nt of ser u m creati ni ne is c o nsi dere d t o ha ve less i ntra -s u bject variati o n, 
a n d will be use d f or t he e G F R deri vati o ns f or t he efficac y  a nalys is.  Si nce it is e x pecte d 
t hat t w o differe nt met h o ds are a p plie d t o t hese t w o sets of bl o o d sa m ples (e nz y matic 
met h o d t o t he batc he d sa m ple a n d rate bla n k met h o d t o t he first sa m ple), t hese t w o sets 
of e G F R data are n ot i nterc ha n gea ble.  I n a d diti o n, t he e G F R la bele d as “ U nsc he d ule d” 
will be use d i n efficac y  a nal ysis if a s u bject has t w o e G F Rs o bser ve d o n t he sa me da y  
a n d sa me ti me.
 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 0 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7 
 
 
 
Or
 
( 3) T he f oll o wi n g S A S c o des will be use d f or t he pri mar y a nalys es:
P R O C  G L M ;
C L A S S  T R E A T M E N T A G E _ S T A T U S  G F R _ S T A T U S  T K V _ S T A T U S ;
W E I G H T  W E I G H T ;
M O D E L  A N N U A L I Z E D _ C H A N G E =  T R E A T M E N T  B A S E L I N E  A G E _ S T A T U S
G F R _ S T A T U S  T K V _ S T A T U S ;
R U N ;
( 4) T he S A S c o de of t he se nsiti vit y a nal ysis of t he pri mar y e n d p oi nt s pecifie d i n 
Secti o n 8. 1. 2 is
P R O C  M I X E D  E M P R I C A L ;
C L A S S  S U B J E C T  T R E A T M E N T A G E _ S T A T U S  G F R _ S T A T U S  T K V _ S T A T U S ;
M O D E L  G F R =  T R E A T M E N T  T I M E  T R E A T M E N T * T I M E  B A S E L I N E
A G E _ S T A T U S  G F R _ S T A T U S  T K V _ S T A T U S ;
R A N D O M  I N T E R C E P T  I T M E / T Y P E = U N  S U B = S U B J E C T  G ;
R U N ;
If t he m o del has a ny c o n ver ge nce pr o ble m, t he varia bles of A G E _ S T A T U S, 
G F R _ S T A T U S, a n d T K V _ S T A T U S ma y be dr o p pe d o ut of t he m o del.
( 5) T he S A S c o de of t he a nal ysis of t he ke y sec o n dar y e n d p oi nt s pecifie d i n 
Secti o n 8. 2. 1 is
P R O C  M I X E D  E M P R I C A L ;
C L A S S  S U B J E C T  T R E A T M E N T A G E _ S T A T U S  G F R _ S T A T U S  T K V _ S T A T U S ;
M O D E L  G F R =  T R E A T M E N T  T I M E  T R E A T M E N T * T I M E  B A S E L I N E
A C U T E _ H E M O D Y N A M I C _ E F F E C T  A G E _ S T A T U S  G F R _ S T A T U S
T K V _ S T A T U S ;
R A N D O M  I N T E R C E P T  I T M E / T Y P E = U N  S U B = S U B J E C T  G ;
R U N ;
If t he m o del has a ny c o n ver ge nce pr o ble m, t he varia bles of A G E _ S T A T U S, 
G F R _ S T A T U S, a n d T K V _ S T A T U S ma y  be dr o p pe d o ut of t he m o del.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 1 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7( 6) T he o n -treat me nt visits i ncl u de d i n t he se nsiti vit y a nalys is of t he ke y sec o n dar y 
e n d p oi nt me nti o ne d i n Secti o n 8. 2. 2 are M o nt hs   T he mea n val ue of 
t hese visits i n m o nt hs is 6. 5.  F or a ne w n u merical a xis wit h its ori gi nal falli n g at 
6. 5 m o nt hs, t he 1 2 ori gi nal ti me p oi nts will bec o me  
o n t his n u merical a xis.  T h us t he c oefficie nts of t he li near 
tre n d c o ntrast of t hese 1 2 m o nt hs are .  Wit h 
treat me nt be c o de d, f or e xa m ple, as 0 f or place b o a n d 1 f or t ol va pta n, t he S A S c o de f or 
t he a nalys is of t he ke y sec o n dar y e n d p oi nt is 
P R O C  M I X E D ;
C L A S S  T R E A T M E N T V I S I T  A G E _ S T A T U S  G F R _ S T A T U S  T K V _ S T A T U S  
S U B J E C T ;
M O D E L  C H A N G E =  T R E A T M E N T  V I S I T  T R E A T M E N T * V I S I T  B A S E L I N E
B A S E L I N E * V I S I T  A G E _ F A C T O R  G F R _ F A C T O R  T K V _ F A C T O R ;
R E P E A T E D  V I S I T / T Y P E = U N  S U B = S U B J E C T ;
L S M E A N S  T R E A T M E N T * V I S I T / P D I F F  C L  A L P H A = 0 . 0 5 ;
E S T I M A T E  ‘ T R E N D  D I F F ’  T R E A T M E N T  0  0
V I S I T  0  0  0  0  0  
T R E A T M E N T * V I S I T  
    
                       ;
R U N ;
If t he esti mate state me nt is n ot esti ma ble, t he fi xe d effects of A G E _ S T A T U S, 
G F R _ S T A T U S, a n d T K V _ S T A T U S ma y  be dr o p pe d o ut of t he m o del.  I n a d diti o n, 
6/ 1 4 3 will be m ulti plie d t o t he esti mate of t he li nea r tre n d c o ntrast i n or der t o pr o vi de a n 
esti mate of treat me nt differe nce i n e G F R sl o pe.   
I n case t here is a c o n ver ge nce pr o ble m i n t he M M R M m o del wit h t he u nstr uct ure d 
varia nce c o varia nce matri x, t he f oll o wi n g varia nce c o varia nce matri x str uct ures will be 
use d i n t he or der of 1) heter o ge ne o us t oe plitz, 2) heter o ge ne o us a ut ore gressi ve of or der 1, 
3) heter o ge ne o us c o m p o u n d s y m metr y , 4) a ut ore gressi ve of or der 1, a n d 5) c o m p o u n d 
s ym metr y .  The first (c o) varia nce str uct ure w hic h d oes n ot ha ve c o n ver ge nce pr o ble m
will be t he o ne use d f or t he a nal ys is.  If a str uct ure d c o varia nce has t o be use d, t he 
“sa n d wic h” esti mat or of t he varia nce c o varia nce matri x of t he fi xe d effects para meters 
will be use d i n or der t o deal wit h p ossi ble m o del miss pecificati o n of t he c o varia nce 
matri x.
( 7) F or a t ol va pta n s u bject w h o ha ve I M P i nterr u pti o n d uri n g t he trial, if t he s u bject 
ha ve e G F R o bser ve d d uri n g t he i nterr u pti o n a n d t he e G F R o bser vati o n is m ore t ha n o ne 
wee k fr o m t he last I M P d ose bef ore t he i nterr u pti o n, t he e G F R o bs er vati o n will be 
fla g ge d ( yes = 1 a n d n o = 0) wit h a t ol va pta n he m o d yna mic effect a n d i ncl u de d i n t he ke y  
sec o n dar y a nalys is.  If t he o bser vati o n is less t ha n o ne wee k b ut m ore t ha n 2 4 h o urs fr o m 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 2 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7t he last IM P d ose bef ore t he i nterr u pti o n, t he o bser vati o n will be e xcl u de d fr o m t he ke y  
sec o n dar y a nalys is.
( 8) O bser vati o ns i n e G F R w hic h are 5 0 % lar ger t ha n a s u bject’s scree ni n g e G F R 
o bser vati o ns will be e xcl u de d fr o m t he pri mar y  a n d sec o n d efficac y a nalys es.
( 9) T he f oll o wi n g met h o d t o deri ve t he wei g ht f or t he pri mar y  a nalys is is pr o p ose d if 
t he n u m ber of e G F R o bser vati o ns is ke pt at 3 i n t he pre-treat me nt baseli ne peri o d.  I n 
or der t o deri ve t he wei g ht use d i n t he wei g hte d a nal y sis, t he f oll o wi n g m o del is 
c o nsi dere d:
yi, 0,k= αi+ ei, 0,k   w here k = 1, 2, K i, 0 ( 1)
yi,j,k= αi+ δi,j+ ei,j,k   w here k = 1, 2, K i,j ( 2)
w here K i, 0 is t he n u m ber of e G F R o bser vati o ns d uri n g t he pre- treat me nt baseli ne peri o d 
f or s u bject i, a n d K i,jis t he n u m ber of e G F R o bser vati o ns d uri n g t he p ost-treat me nt 
f oll o w-u p peri o d f or s u bject i, wit h visit j as t he visit M o nt h 1 2 f or c o m pleters or ma p pe d 
re g ular visits f or early dr o p o uts.  α iis a ra n d o m varia ble f or t he “real” e G F R baseli ne of 
s u bject i, a n d t his varia ble will be ca ncelle d o ut f or c ha n ge fr o m baseli ne.  δ i,jis a ra n d o m 
varia ble f or c ha n ge fr o m pre -treat me nt baseli ne f or s u bject i t o visit j.  T hese δ i,js are 
n or mall y  distri b ute d, wit h mea ns bei n g δ P,jf or place b o s u bjects a n d δ T,jf or t ol va pta n 
s u bjects, a n d varia nce   δ,j2.  T hese δ i,js are s u p p ose d t o be in de pe n de nt fr o m s u bject t o 
s u bject, a n d eac h s u bject has o nl y o ne p ost-baseli ne visit j i n t he pri mar y a nal ysis.  I n 
a d diti o n, α is are ass u me d ii d n or mall y distri b ute d, e i,j,kare ass u me d ii d N( 0,  2), a n d all 
t hese ra n d o m varia bles are m ut uall y i n de pe n dent.  T heir a vera ge o ver t he K i, 0
o bser vati o ns at baseli ne a n d t he K i,jo bser vati o ns at p ost -treat me nt f oll o w-u p will be :
ӯi, 0 = αi+ ēi, 0,   w here ē i, 0~ N( 0,  2/ Ki, 0) ( 3)
ӯi,j = αi+ δi,j+ ēi,j,   w here ē i,j~ N( 0,  2/ Ki,j) ( 4)
t he distri b uti o n of t heir differe nce is :
ӯi,j  - ӯi, 0 =  δi,j+ ēi,j- ēi, 0~  N(.,   δ,j2+  2( 1/ K i, 0+ 1/ K i,j)), ( 5)
w here t he mea n of t he n or mal distri b uti o n is δ P,jf or place b o s u bjects a n d δ T,jf or t ol va pta n 
s u bjects.  
I n or der t o esti mate t he varia nce c o m p o ne nts gi ve n i n ( 5), a f urt her ass u m pti o n of all 
 δ,j2’s are e q ual, ie,   δ,j2 = δ2 is ma de, si nce t here ma y n ot be e n o u g h s u bjects wit h dra w 
t o sta bilize d t he esti mate of   δ,j2at s o me visits.  In a d diti o n, it is ass u me d all s u bjects get 
3 e G F R o bser vati o ns at baseli ne.  T his ass u m pti o n is reas o na ble, si nce us uall y  s u bjects 
f oll o w pr ot oc ol sc he d ules m ore strictl y at t he be gi n ni n g of t he trial, a n d c o ul d si m plif y 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 3 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7t he esti mati o n of t he varia nce c o m p o ne nts.  T he n, a f or m ula of c ha n ge fr o m baseli ne ca n 
be writte n si milar t o ( 5) f or t he esti mati o n of t he varia nce c o m p o ne nts:
yi,j,k  - ӯi, 0 =  δi,j+ ei,j,k- ēi, 0~  N(.,   δ2+  2( 1 + 1/ 3)), ( 6)
A mi xe d m o del wit h fi xe d effect fact ors of treat me nt neste d wit hi n visit, re plicati o n (f or 
t he re peate d o bser vati o ns at t he p ost-treat me nt f oll o w-u p i n e G F R) will be a p plie d t o 
c ha n ge fr o m baseli ne (as t he a vera ge of t he 3 pre -treat me nt e G F R o bser vati o ns) i n e G F R 
o bser ve d at eac h re plicati o n.  I n t his mi xe d m o del, re plicati o ns at t he p ost -treat me nt 
f oll o w-u p are c o nsi dere d as t he re peate d meas ure me nts, wit h a c o m p o u n d s y m metric 
varia nce matri x str uct ure.  I n t his esti mate d varia nce -c o varia nce matri x, t he di a g o nal 
ele me nts are t he esti mate of   δ2+  2( 1 + 1/ 3), a n d t he off dia g o nal ele me nts are t he 
esti mate of   δ2+  2( 1/ 3).  S ol vi n g t hese t w o e q uati o ns will get t he esti mates of   δ2a n d 
 2.  Wit h t hese varia nce c o m p o ne nt esti mates, t he varia nce gi ve n i n f or m ula ( 5) is 
esti mate d f or eac h s u bject.  Di vi di n g t he esti mate d varia nce gi ve n i n ( 5) b y t he s u bject’s 
trial d urati o n will pr o vi de a n esti mate d varia nce f or t he s u bject’s a n n ualize d c ha n ge i n 
e G F R.  T he i n verse of t his esti mate d varia nce will be t he we i ght of t he s u bject use d i n t he 
pri mar y  a nalys is.
S A S c o de f or t he esti mati o n of varia nce c o m p o ne nt
P R O C  M I X E D ;
C L A S S  S U B J E C T  V I S I T  T R E A T M E N T  R E P L I C A T I O N ;
M O D E L  C H A N G E  =  T R E A T M E N T ( V I S I T )  R E P L I C A T I O N ;
R E P E A T E D  R E P L I C A T I O N / T Y P E = C S  S U B = S U B J E C T ;
R U N ;
I n t his esti mati o n of varia nce c o m p o ne nts, it is ass u me d t he p ost-treat me nt f oll o w- u p 
e G F R o bser vati o ns of earl y  wit h dre w s u bjects are ma p pe d i nt o sc he d ule d visits.  Si nce 
t he m o nt hl y sc he d ule d visits i n t his pr ot oc ol, f or a s u bject early wit h dre w I M P, c o m pare d 
t o t he s u bject’s last sc he d ule d o n-treat me nt visit, if t he first p ost-treat me nt f oll o w- u p 
e G F R is o bser ve d less or e q ual t o 2 5 da y s ( = 1 5 + 7 + 3) after t he last sc he d ule d o n 
treat me nt visit, t he n t he s u bject’s p ost-treat me nt f oll o w-u p e G F R o bser vati o ns will be 
ma p pe d t o t he s u bject’s last sc he d ule d o n -treat me nt visit; ot her wise, if t he first p ost-
treat me nt f oll o w-u p e G F R is o bser ve d less or e q ual t o 5 5. 5 da y s ( = 3 0. 5 + 1 5 + 7 + 3) 
after t he last sc he d ule d o n treat me nt visit, t he n t he s u bject’s p ost -treat me nt f oll o w- u p 
e G F R o bser vati o ns will be ma p pe d t o o ne m o nt h after t he s u bject’s last sc he d ule d o n -
treat me nt visit; etc.
( 1 0) T he f oll o wi n g met h o d t o deri ve t he wei g ht f or t he pri mar y a nalys is is pr o p ose d in 
case t he bli n de d sa m ple size re-esti mati o n l ea ds t o a c ha n ge i n t he n u m ber of e G F R 
o bser vati o ns i n pre -treat me nt baseli ne peri o d, s o t hat t he ass u m pti o n of e q ual n u m ber of 
pre -treat me nt baseli ne e G F R o bser vati o ns is n o l o n ger.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 4 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7I n or der t o deri ve t he wei g ht use d i n t he wei g hte d a nalys is, t he f oll o wi ng m o del is 
c o nsi dere d:
yi, 0,k= αi+ ei, 0,k   w here k = 1, 2, K i, 0 ( 1)
yi, 1,k= αi+ δi+ ei, 1,k   w here k = 1, 2, K i, 1 ( 2)
w here K i, 0 is t he n u m ber of e G F R o bser vati o ns d uri n g t he pre -treat me nt baseli ne peri o d 
f or s u bject i, a n d K i, 1is t he n u m ber of e G F R o bser vati o ns d uri n g t he p ost-treat me nt 
f oll o w-u p peri o d f or s u bject i, w het her s u bject i c o m pletes t he st u d y or n ot.  α iis a 
ra n d o m varia ble f or f or t he “real” e G F R baseli ne of s u bject i, a n d t his effect will be 
ca ncelle d o ut f or c h a n ge fr o m baseli ne.  δ i,is a ra n d o m varia ble f or t he “real” c ha n ge 
fr o m baseli ne t o p ost-treat me nt f oll o w-u p of s u bject i .  T hese δ is are n or mall y 
distri b ute d, wit h a c o m m o n varia nce   δ2, a n d are i n de pe n de nt fr o m s u bject t o s u bject.  In 
a d diti o n, α is are ass u me d ii d n or mall y distri b ute d, e i, 1,kare ass u me d ii d N( 0,  2), a n d all 
t hese ra n d o m varia bles are m ut uall y i n de pe n de nt.  T heir a vera ge o ver t he K i, 0
o bser vati o ns at baseli ne a n d t he K i, 1o bser vati o ns at p ost -treat me nt f oll o w-u p will be :
ӯi, 0 = αi+ ēi, 0,   w here ē i, 0~ N( 0,  2/ Ki, 0) ( 3)
ӯi, 1 = αi+ δi+ ēi, 1,   w here ē i, 1~ N( 0,  2/ Ki, 1) ( 4)
t he distri b uti o n of t he c ha n ge fr o m baseli ne f or s u bject i is:
ӯi, 1  - ӯi, 0 =  δi+ ēi, 1- ēi, 0~  N(.,   δ2+  2( 1/ K i, 0+ 1/ K i, 1)) ( 5)
T he esti mati o n of  2is si m pl y pr o vi de d by:
ve= ½ { Σ iΣk(yi, 0,k  - ӯi, 0)2/ Σi( Ki, 0 - 1) + Σ iΣk(yi, 1,k  - ӯi, 1)2/ Σi( Ki, 1 - 1)} ( 6)
w here Σ is u ms o ver all s u bject i, a n d Σ ks u ms o ver all re plicate k f or s u bject i, eit her at 
baseli ne visit or p ost -treat me nt f oll o w-u p visit.  Let
di = ( ӯ i, 1- ӯi, 0)/ ti~  N(.,[   δ2+  2( 1/ K i, 0+ 1/ K i, 1)]/ t i2) ( 7)
bei n g t he a n n ualize d c ha n ge fr o m baseli ne of s u bject i a n d its distri b uti o n, w here t iis t he 
trial d urati o n t o a n n ualize t he pri mar y e n d p oi nt f or s u bject i, wit h mea n β Ta n d β Pf or 
t ol va pta n a n d place b o s u bjects res pecti vel y.  Let
τi= [ δ2+  2( 1/ K i, 0+ 1/ K i, 1)]/ t i2( 8)
T he treat me nt a vera ges are :
d ̅T= Σ i i n T L V  di / nT a n d d ̅ P= Σ i i n P L C  di / nP ( 9)
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 5 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7w here  Σ i i n T L V (Σi i n P L C ) s u ms o ver all t ol va pta n ( place b o) s u bjects, a n d n T (nP) is t he 
t otal n u m ber of s u bjects i n t ol va pta n ( place b o).  Let
v = ½ { Σ i i n T L V ( di  – d̅T)2/( nT – 1) + Σ i i n P L C ( di – d ̅P)2/( nP – 1)} ( 1 0)
Si nce
Σi i n T L V ( di  – d ̅T)2= Σ i ≠  i’i n T L V  ( di – di’)2/ 2 nT   a n d
Σi i n P L C ( di  – d ̅P)2= Σ i ≠  i’i n P L C  ( di – di’)2/ 2 nP   ( 1 1)
f or m ula ( 1 0) ca n be re writte n as:
v =  Σ i ≠  i’ i n T L V ( di – di’)2/[ 4 n T( nT – 1)]  + Σ i ≠  i’ i n P L C ( di – di’)2/[ 4 n P( nP – 1)] ( 1 2)
a n d
E(v) =  Σ i ≠  i’ i n T L V (τi+ τi’)/[ 4 n T( nT – 1)]  + Σ i ≠  i’ i n P L C (τi+ τi’)/[ 4 n P( nP – 1)]
        = Σi ≠  i’i n T L V {[ δ2+  2( 1/ K i, 0+ 1/ K i, 1)]/ t i2+ [   δ2+  2( 1/ K i’, 0+ 1/ K i’, 1)]/ t i’2}/[ 4 n T( nT – 1) ]
                     + Σ i ≠  i’i n P L C {[ δ2+  2( 1/ K i, 0+ 1/ K i, 1)]/ t i2+ [   δ2+  2( 1/ K i’, 0+ 1/ K i’, 1)]/ t i’2}/[ 4 n P( nP – 1) ]
                     = Σ i i n T L V {[ δ2+  2( 1/ K i, 0+ 1/ K i, 1)]/ t i2}/(2 n T) +  Σ i i n P L C [ δ2+  2( 1/ K i, 0+ 1/ K i, 1)]/ t i2}/(2 n P)
                     =  δ2 [Σi i n T L V  1/( 2 n Tti2) +  Σ i i n P L C 1/( 2 n Pti2)] 
                     +  2 [Σi i n T L V  ( 1/ K i, 0+ 1/ K i, 1)/(2 n Tti2) +  Σ i i n P L C ( 1/ K i, 0+ 1/ K i, 1)/(2 n Pti2)] ( 1 3)
w here E( v) is t he e x pectati o n of v.  T h us, t he esti mate of   δ 2 is :
vδ= {v - v e[ Σi i n T L V  ( 1/ K i, 0+ 1/ K i, 1)/(2 n Tti2) +  Σ i i n P L C ( 1/ K i, 0+ 1/ K i, 1)/(2 n Pti2)]}
                     /[ Σ i i n T L V  1/( 2 n Tti2) +  Σ i i n P L C 1/( 2 n Pti2)] ( 1 4)
A n d t he esti mate d varia nce of t he a n n ualize d c ha n ge fr o m baseli ne f or s u bject i (d i) is:
[vδ+ ve( 1/ K i, 0+ 1/ K i, 1)] / t i2( 1 5)
T he reci pr ocal of ( 1 5) will be t he wei g ht f or s u bject i use d i n t he wei g hte d a nal ys is.
( 11 ) Ma p pi n g of u nsc he d ule d visit a n d e n d of treat me nt visit d uri n g d o u ble- bli n d 
treat me nt peri o d t o n o mi nal visits:  In ge neral, t hese visits will be ma p pe d i nt o t he 
m o nt hl y  n o mi nal visits base d o n t he mi d-p oi nt bet wee n t w o m o nt hl y  visits, ie, if a n 
u nsc he d ule d visit or a n e n d of treat me nt visit is wit hi n 1 5 da y s of t he pre vi o us visit, it 
will be ma p pe d t o t he pre vi o us visit; if it is greater t ha n 1 5 da y  of t he pre vi o us visit, it 
will be ma p pe d t o ne xt a p pr o priate visit, wit h 3 0. 5 da y s (r o u n d if necessar y) bet wee n 
eac h t w o a djace nt n o mi nal visits.  I f a n u nsche d ule d visit or a n e n d of treat me nt visit falls 
i nt o 3 5 1 (r o u n de d fr o m 3 0. 5 x 1 1 + 1 5) t o 3 8 1 ( = 3 6 6 + 1 5) da ys p ost -ra n d o mizati o n, it 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 6 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7will be ma p pe d t o visit M o nt h 1 2.  I f a n u nsc he d ule d visit or a n e n d of treat me nt visit is 
m ore t ha n 2 da y s p ost last d ose, it will n ot be ma p pe d t o t hese d o u ble-bli n d n o mi nal 
visits, b ut will be c o n si dere d f or t he p ost-treat me nt foll o w -u p visits, if it falls wit hi n 7 t o 
4 0 da y s fr o m t he last d ose of I M P.  
( 12) T he f oll o wi n g reas o ns are c ollecte d i n t he C R F f or s u bjects w h o disc o nti n ue I M P:
1. Disc o nti n ue d base d o n s u bject decisi o n:
1. 1. I M P n ot t olera ble ( A E w hic h is a n n o yi n g or u nc o mf orta ble b ut n ot seri o us or 
hazar d o us)
1. 2. Reas o n ot her t ha n t olera bilit y
1. 2. 1. Pre g na nc y
1. 2. 2. Trial t o o b ur de ns o me
1. 2. 3. Ot her reas o n
1. 3. Ta ki n g mar kete d pr o d uct f or t ol va pta n
2. Disc o nti n ue d base d o n p h y sicia n decisi o n
2. 1. P ote ntial I M P -relate d safet y c o ncer n or seri o us A R placi n g s u bject at u n d ue 
hazar d
2. 2. Pr o gressi o n of disease lea di n g t o dial ys is, tra ns pla ntati o n or e G F R decli ne
2. 3. He patic A E
3. Ot her
3. 1. S u bject deat h
3. 2. S u bject l ost t o f oll o w - u p
I n Secti o n 8. 2. 4 f or se nsiti vit y a nalys is i ncl u di n g i m p utati o n of missi n g data, si x reas o ns 
of disc o nti n uati o n of I M P were liste d i n t he or der of t heir li keli h o o d t o be M N A R.  T he 
ma p pi n g of t he reas o ns of di sc o nti n uati o n of IM P t o t he reas o ns use d i n t he se nsiti vit y  
a nal ys is is pr o vi de d bel o w:
 Pr o gressi o n of re nal disease or Lac k of efficac y :  Ite m 2. 2
 Ot her A E:  Ite ms of 1. 2. 3, 2. 1, 2. 3, 3, 1 a n d 3. 2
 A q uaretic A E:  I te m 1. 1
 Trial t o o b ur de ns o me:  Ite ms of 1. 2 . 1 a n d 1. 2. 2
 C o m mercial t ol va pta n f or A D P K D a vaila ble:  Ite m 1. 3
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 7 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7T he reas o n t o ma p Ite ms of 1. 2. 3 ( Ot her reas o ns u n der Reas o n ot her t ha n t olera bi lit y) a n d 
3. 2 ( S u bject l ost t o f oll o w -u p) t o ot her A E is f or c o nser vati ve ness t o c o nsi der t he m as a 
reas o n t o be m ore li kel y M N A R. 
8. 4 S u b gr o u p Effi c a c y  An al y si s
S u b gr o u p a nal ys es will be pr o vi de d t o t he pri mar y a n d t he ke y  sec o n dar y e n d p oi nts b y 
re gi o n ( U S a n d n o n-U S), ge n der ( male a n d fe male), race ( Ca ucasia n a n d Ot her races), 
a ge (≤ 5 5 y ears or n ot), baseli ne G F R l e vel  
, a n d baseli ne T otal Ki d ne y v ol u me , a n d b y C K D 
Sta ge.
8. 5 E x pl or at or y  An al y si s
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
  
 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 8 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7r u n;
9 S af et y  An al y s i s
I n ge neral, baseli ne meas ure me nts of safet y varia bles are defi ne d as t heir last 
meas ure me nts pri or t o t he ra n d o mizati o n f or t he pri mar y safet y p o p ulati o n (e xce pt f or 
ser u m creati ni ne, w hic h is defi ne d si milar t o t he baseli ne of e G F R assess me nt f or t he 
pri mar y  e n d p oi nt) a n d as t heir last meas ure me nts pri or t o t he first d osi n g of st u d y 
me dicati o n f or t he sec o n dar y safet y p o p ulati o n.  Safet y a nalys is will be c o n d ucted base d 
o n t he se safety p o p ulati o n s, w hic h are defi ne d i n Secti o n 5. 1 .  Sta n dar d safet y varia bles 
t o be a nalyz e d i ncl u de A Es, cli nical la b orat or y tests, a n d vital si g ns.  I n ge neral, 
s u m marize d statistics of c ha n ges fr o m baseli ne will be pr o vi de d f or safet y var ia bles 
base d o n all a vaila ble data.  Pr o p ose d ta bles a n d fi g ures t o be ge nerate d f or t he safet y 
a nal ys is ca n be f o u n d i n A p pe n di x 3 a n d A p pe n di x 4 .
9. 1 A d v er s e E v e nt s
All A Es will be c o de d b y s y ste m or ga n class a n d Me dical Dicti o nar y f or Re g ulat or y 
Acti vities ( Me d D R A) preferre d ter m.  T he i nci de nce of t he f oll o wi n g e ve nts will b e 
s u m marize d b y treat me nt gr o u p f or t he pri mar y safet y p o p ulati o n; su m mar y of t hese 
e ve nts will als o be pr o vi de d f or t he sec o n dar y  safet y p o p ulati o n:
a) T E A Es b y  se verity
b) P ote ntiall y  dr u g-relate d T E A Es
c) T E A Es wit h a n o utc o me of deat h
d) Seri o us T E A Es
e) Disc o nti n uati o ns d ue t o T E A Es
9. 2 Cli ni c al L a b or at or y  D at a
S u m mar y  statistics f or c ha n ges fr o m baseli ne i n t he ce ntral cli nical la b orat or y 
meas ure me nts wi ll be pr o vi de d f or t he pri mar y a n d sec o n dar y safety p o p ulati o ns .  
P ote ntiall y  cli nicall y si g nifica nt res ults i n la b orator y  tests i de ntifie d usi n g pr os pecti vely 
defi ne d criteria will als o be s u m marize d f or t he pri mar y a n d sec o n dar y safet y p o p ulati o ns 
as well.  Criteria of p ote ntiall y  cli nicall y si g nifica nt la b test a b n or malities are pr o vi de d i n 
A p pe n di x 1 . 
I n a d diti o n, la b orat or y meas ure me nts t hat si g nal t he p ote ntial f or H y ’s La w will be 
re p orte d.  A n i nci de nce ta ble a n d a listi n g will be pr o vi de d f or s u bjects w h o meet o ne or 
co m bi nati o ns of f oll o wi n g criteria , wit h o ut i nitial fi n di n gs of c h olestasis (ser u m al kali ne 
p h os p hatase ( A L P) acti vit y  > 2 x U L N):
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 2 9 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7Ala ni ne a mi n otra nsferase (A L T ) or as partate a mi n otra nsferase ( A S T )  3 x u p per 
li mit of n or mal (U L N)
B ilir u bi n  2 x U L N 
9. 3 P h y si c al E x a mi n ati o n , a n d Vit al Si g n s D at a
B y -patie nt listi n gs will be pr o vi de d f or p h y sical e xa mi nati o n.  S u m mar y statistics f or 
c ha n ges fr o m baseli ne i n vital si g ns a n d p ote ntiall y  cli nicall y si g nifica nt res ults i n vital 
si g ns will be s u m marize d f or t he pri mar y safety p o p ulati o n as well as t he sec o n dar y 
safety p o p ulati o n .
I nci de nce of p ote ntiall y cli nicall y si g nifica nt vital si g n res ults will als o be s u m marize d b y  
treat me nt gr o u ps.  Criteria of p ote ntiall y cli nically si g nifica nt vital si g n a b n or malities are 
pr o vi de d i n A p pe n di x 2 .
1 0 I nt eri m An al y s i s
A n o pti o nal i nteri m a nal ysis was pla n ne d b ut will n ot be c o n d ucte d, beca use, gi ve n t he 
ra pi d fi nal e nr oll me nt, t he s p o ns or, u p o n recei vi n g rec o m me n dati o n fr o m t he trial’s 
Steeri n g C o m mittee, dee me d t he a nal ys is mi g ht o nl y bri n g a fe w m o nt h’s differe nce i n 
trial c o ncl usi o n.  T h us, wit h o ut t he i nteri m a nal ysis, t he al p ha le vel of t he fi nal a nalys is 
will be 0. 0 5.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 0 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 71 1 R ef er e n c e
1Lefa nte JJ. T he p o wer t o detect differe nces i n a vera ge rates of c ha n ge i n l o n git u di nal 
st u dies.  Statistics i n Me dici ne, 9, 4 3 7- 4 4 6, 1 9 9 0.
2Nati o nal Researc h C o u ncil ( U S) Pa nel o n Ha n dli n g Missi n g Data i n Cli nical Trials. 
T he Pre ve nti o n a n d Treat me nt of Missi n g Data i n Cli nical Trials. Was hi n gt o n ( D C): 
Nati o nal Aca de mies Press ( U S); 2 0 1 0.
3Ste ve ns L A, Sc h mi d C H, Gree ne T, Z ha n g Y, Bec k GJ, Fr oissart M, Ha m m L L, 
Le wis J B, Ma uer M, Na vis GJ, Steffes M W, E g gers P W, C ores h J a n d L e ve y A S. 
C o m parati ve Perf or ma nce of t he C K D E pi de mi ol o g y  C olla b orati o n ( C K D-E PI) a n d 
M o dificati o n of Diet i n Re nal Disease ( M D R D) St u d y  E q uati o ns f or Esti mati n g G F R 
Le vels A b o ve 6 0 m L/ mi n/ 1. 7 3 m 2. A m J Ki d ne y  Dis. 2 0 1 0, 5 6: 4 8 6- 4 9 5.
4H ori o M, I mai E, Yas u da Y, Wata na be T a n d Mats u o S. M o dificati o n of t he C K D 
E pi de mi ol o g y  C olla b orati o n ( C K D-E PI) E q uati o n f or Ja pa nese: Acc urac y  a n d use f or 
P o p ulati o n Esti mates. A m J Ki d ne y  Dis. 2 0 1 0; 5 6: 3 2- 3 8.
5T her nea u, T M a n d Gra m bsc h, P M. M o deli n g S ur vi val Data: E xte n di n g t he C o x 
M o del.  S pri n g -Verla g, Ne w Y or k. 2 0 0 0.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 1 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7A p pe n di x 1 Criteri a of P ote nti all y Cli nic all y Si g nific a nt L a b or at or y Test 
A b n or m alities ( M o difie d N CI Criteri a)
L a b or at or y Test A b n or m alities d ue t o Test V al ue I ncre ase
Test A b n or m alit y Test Res ult Gr a de
0 1 2 3 4
A P T T (sec) I ncrease U L N > U L N -
1. 5 x U L N> 1. 5 x U L N -
2 x U L N> 2 x U L N
A L T ( S G P T) 
(I U/ L)I ncrease U L N > U L N -
3 x U L N> 3 x U L N -
5 x U L N> 5 x U L N -
2 0 x U L N> 2 0 x U L N
A S T ( S G O T) 
(I U/ L)I ncrease U L N > U L N -
3 x U L N> 3 x U L N -
5 x U L N> 5 x U L N -
2 0 x U L N> 2 0 x U L N
Bilir u bi n, T otal 
( mg/ d L)I ncrease U L N > U L N -
2 x U L N> 2 x U L N -
3 x U L N> 3 x U L N -
1 0 x U L N> 1 0 x U L N
Creati ni ne 
( mg/ d L)I ncrease Pre-
ra n d o mizati o nA B * > A B –
1. 5 x A B> 1, 5 x A B –
3 x A B> 3 x A B –
6 x A B> 6 x A B
Creati ni ne 
( mg/ d L)I ncrease P ost -
ra n d o mizati o n< 1. 3 3 x 
P R *1. 3 3 x P R -
< 2 x P R2 x P R – < 3 
x P R3 x P R – 6 x 
P R> 6 x P R
E osi n o p hils, 
A bs ol ute 
( T h o us/ μ L)I ncrease ≤ 0. 6 5 > 0. 6 5 -
1. 5> 1. 5 - 5 > 5 -
Gl uc ose ( m g/ d L) I ncrease ≤ 1 1 5 > 1 1 5 -
1 6 0> 1 6 0 - 2 5 0 > 2 5 0 - 5 0 0 > 5 0 0
H e m o gl o bi n 
( g/ d L)I ncrease U L N > U L N -
2 0> 2 0 - 2 1 > 2 1 - 2 2. 5 > 2 2. 5
P otassi u m 
( mE q/ L)I ncrease U L N > U L N -
5. 5> 5. 5 - 6 > 6 - 7 > 7
I N R I ncrease U L N > U L N -
1. 5 x U L N> 1. 5 x U L N -
2 x U L N> 2 x U L N -
S o di u m ( m g/ d L) I ncrease < 1 4 5 1 4 6 - 1 5 0 1 5 1 - 1 5 5 1 5 6 - 1 6 0 > 1 6 0
Tri gl yceri des 
( mg/ d L)I ncrease U L N > U L N -
2. 5 x U L N> 2. 5 x U L N -
5 x U L N> 5 x U L N -
6 x U L N> 6 x U L N
Urea Nitr o ge n 
( mg/ d L)I ncrease ≤ 2 2 > 2 2 - 2 6 > 2 6 - 3 1 > 3 1 -
W hite Bl o o d 
C o u nt 
( T h o us/ μ L)I ncrease ≤ 1 0. 7 9 9 > 1 0. 7 9 9 -
1 5> 1 5 - 2 0 > 2 0 - 2 5 > 2 5
* Baseli ne creati ni ne is e x pecte d t o be ele vate d i n t his p o p ulati o n. A vera ge baseli ne ( A B) is e q ual t o t he 
mea n baseli ne val ue c ollecte d d uri n g scree ni n g peri o d. 
D uri n g treat me nt wit h t ol va pta n, ser u m creati ni ne is e x pecte d t o i ncrease b y a p pr o xi matel y 5 t o 1 0 %. 
P ost -ra n d o mizati o n baseli ne ( P R) is e q ual t o t he hi g hest val ue o btai ne d d uri n g t he r u n-i n peri o d 
matc hi n g t he s u bject’s assi g ne d treat me nt, ie, eit her place b o or t ol v a pta n r u n -i n peri o ds.
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 2 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7L a b or at or y Test A b n or m alities d ue t o Test V al ue Decre ase
Test A b n or m alit y Test Res ult Gr a de
- 4 - 3 - 2 - 1 0
Gl uc ose 
( mg/ d L)Decrease < 3 0 3 0 - < 4 0 4 0 - < 5 5 5 5 - < 6 5 ≥ 6 5
H e m o gl o bi n 
( g/ d L)Decrease < 6. 5 6. 5 - < 8 8 - < 1 0 1 0 - < L L N L L N
L y m p h oc ytes, 
A bs ol ute 
( T h o us/ μ L)Decrease < 0. 2 0. 2 - < 0. 5 0. 5 - < 0. 8 0. 8 - < L L N L L N
Ne utr o p hils, 
A bs ol ute 
( T h o us/ μ L)Decrease < 0. 5 0. 5 - < 1 1 - < 1. 5 1. 5 - < L L N L L N
Platelet C o u nt 
( T h o us/ μ L)Decrease < 2 5 2 5 - < 5 0 5 0 - < 7 5 7 5 - < L L N L L N
P otassi u m 
( mE q/ L)Decrease < 2. 5 2. 5 - < 3 - 3 - < L L N L L N
S o di u m 
( mg/ d L)Decrease < 1 2 0 1 2 0 - 1 2 4 1 2 5 - 1 2 9 1 3 0 - 1 3 5 ≥ 1 3 6
W hite Bl o o d 
C o u nt 
( T h o us/ μ L)Decrease < 1 1 - < 1. 5 1. 5 - < 2. 5 2. 5 - < 3. 5 0 1 ≥ 3. 5 0 1
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 3 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7A p pe n di x 2  Criteri a of P ote nti all y Cli nic all y Si g nific a nt Vit al 
Si g n A b n or m alities
Test T y pe Test P ar a m eters U nit Se x Criteri a ( m eet eit her o ne will c o u nt)
Li mit C h a n ge fr o m  b aseli ne
VI T A L SI G N S S B P, SI T TI N G m m H g Male/ Fe male ≥ 1 8 0 ≥ 2 0
VI T A L SI G N S S B P, SI T TI N G m m H g Male/ Fe male ≤ 9 0 ≤ − 2 0
VI T A L SI G N S D B P, SI T TI N G m m H g Male/ Fe male ≥ 1 0 5 ≥ 1 5
VI T A L SI G N S D B P, SI T TI N G m m H g Male/ Fe male ≤ 5 0 ≤ − 1 5
VI T A L SI G N S H E A R T R A T E b p m Male/ Fe male ≥ 1 2 0 ≥ 1 5
VI T A L SI G N S H E A R T R A T E b p m Male/ Fe male ≤ 5 0 ≤ − 1 5
VI T A L SI G N S T E M P E R A T U R E de gree C Male/ Fe male ≥ 3 8. 3 ≥ 1. 1
VI T A L SI G N S W EI G H T k g Male/ Fe male - ≥ 7 perce nt 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 4 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7A p pe n di x 3 T a ble of C o nte nts f or Cli nic al T a bles
C T -1. 1. 1   S u bject Dis p ositi o n   Scree ne d S u bjects
C T -1. 1. 2   S u bject Dis p ositi o n   Ra n d o mize d S u bjects
C T -1. 1. 3   S u bject P o p ulati o ns f or A nal ys is   E nr olle d S u bjects
C T -1. 1. 4   S u bject Dis p ositi o n b y  Re gi o n - U S a n d N o n -U S
C T -1. 1. 5   S u bject Dis p ositi o n b y  Ce nter
C T -1. 2. 1. 1   N u m ber of S u bjects wit h A vaila ble Baseli ne a n d O n -treat me nt Ser u m 
Creati ni ne Res ults b y  Visit   E nz ymatic Met h o d   Ra n d o mize d S u bjects
C T -1. 2. 1. 2   N u m ber of S u bjects wit h A vaila ble Baseli ne a n d O n -treat me nt Ser u m 
Creati ni ne Res ults b y  Visit   Rate Bla n ke d Met h o d   Ra n d o mize d S u bjects
C T -1. 2. 2. 1   N u m ber of S u bjects wit h A vaila ble Ser u m Creati ni ne Res ults f or Pre -
treat me nt Baseli ne a n d P ost -treat me nt F oll o w-u p Visits   E nz y matic Met h o d   
Ra n d o mize d S u bjects
C T -1. 2. 2. 2   N u m ber of S u bjects wit h A vaila ble Ser u m Creati ni ne Res ults f or Pre -
treat me nt Baseli ne a n d P ost-treat me nt F oll o w-u p Visits   Rate Bla n ke d Met h o d   
Ra n d o mize d S u bjects
C T -1. 2. 2. 3   N u m ber of S u bjects wit h A vaila ble Ser u m Creati ni ne Res ults f or Pre -
treat me nt Baseli ne a n d P ost-treat me nt F oll o w-u p Visits   E nz y matic Met h o d   C o m pleters 
( O n a n d Off Treat me nt)
C T -1. 2. 2. 4   N u m ber of S u bjects wit h A vaila ble Ser u m Creati ni ne Res ults f or Pre -
treat me nt Baseli ne a n d P ost-treat me nt F oll o w-u p Visits   Rate Bla n ke d Met h o d   
C o m pleters ( O n a n d Off Treat me nt)
C T -1. 2. 3. 1   N u m ber of S u bjects wit h A vaila ble Off -treat me nt Ser u m Creati ni ne Res ults 
b y  Visit after Disc o nti n uati o n of St u d y  Me dicati o n   E nz ymatic Met h o d   Ra n d o mize d 
S u bjects
C T -1. 2. 3. 2   N u m ber of S u bjects wit h A vaila ble Off -treat me nt Ser u m Creati ni ne Res ults 
b y  Visit after Disc o nti n uati o n of St u d y Me dicati o n   Rate Bla n ke d Met h o d   Ra n d o mize d 
S u bjec ts
C T -2. 1   Reas o ns f or Disc o nti n uati o n fr o m St u d y    Ra n d o mize d S u bjects
C T - 2. 2   Reas o ns f or Disc o nti n uati o n fr o m Treat me nt   Ra n d o mize d S u bjects
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 5 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -3. 1. 1   De m o gra p hic C haracteristics - Ra n d o mize d, D o u ble -bli n d Treat me nt Peri o d
C T -3. 1. 2   De m o gra p hic C haracteristics - Pri mar y Safet y  P o p ulati o n, D o u ble-bli n d 
Treat me nt Peri o d
C T -3. 1. 3   De m o gra p hic C haracteristics - Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d 
T ol va pta n Treat me nt Peri o d
C T -3. 1. 4   Baseli ne C haracteristics - D o u ble -bli n d Treat me nt Peri o d
C T - 3. 2. 1   Stratificati o n Criteria at Ra n d o mizati o n - Ra n d o mize d S u bjects
C T -3. 3. 1   A D P K D Me dical Hist or y    Ra n d o mize d S u bjects
C T -3. 3. 2   A D P K D Me dical Hist or y  - Ki d ne y  Pai n   Ra n d o mize d S u bjects
C T -3. 3. 3   A D P K D Me dical Hist or y  - N o n -pai n Relate d Ki d ne y  S ur ger y   Ra n d o mize d 
S u bjects
C T -3. 3. 4   A D P K D Me dical Hist or y  - He patic Cys ts ( Li ver C ysts)   Ra n d o mize d S u bjects
C T -3. 3. 5   A D P K D Me dical Hist or y  - Ot her P ol y c ystic Ki d ne y Disease C o m or bi dit y   
Ra n d o mize d S u bjects
C T -4. 1. 1   C o nc o mita nt Me dicat i o ns: Ta ke n Pri or t o Si n gle-bli n d T ol va pta n Titrati o n 
Peri o d   Ra n d o mize d S u bjects
C T - 4. 1. 2   C o nc o mita nt Me dicati o ns: Ta ke n D uri n g Si n gle- bli n d T ol va pta n Treat me nt 
Peri o d   Ra n d o mize d S u bjects
C T -4. 1. 3   C o nc o mita nt Me dicati o ns: Ta ke n D uri n g D o u ble -bli n d Treat me nt Peri o d   
Ra n d o mize d S u bjects
C T -4. 1. 4   C o nc o mita nt Me dicati o ns: Ta ke n After St u d y  T hera py   Ra n d o mize d S u bjects
C T -5. 1. 1   Pri mar y  E n d p oi nt: Wei g hte d A N C O V A of A n n ualize d C ha n ge i n e G F R 
( C K D-E PI) fr o m Pre -treat me nt Baseli ne t o P ost-treat me nt F oll o w -u p ( m L / mi n/ 1. 7 3 
m 2/ y r)
C T -5. 1. 2   Se nsiti vit y  A nal ysis of Pri mar y E n d p oi nt: Wei g hte d A N C O V A of A n n ualize d 
C ha n ge i n e G F R ( C K D -E PI ) fr o m Pre-treat me nt Baseli ne
C T -5. 1. 3   Se nsiti vit y  A nal ysis of Pri mar y E n d p oi nt: Li near Mi xe d Effect M o del of 
e G F R ( C K D-E PI) C ha n ge Sl o pe ( m L / mi n/ 1. 7 3 m 2/ yr)
C T -5. 1. 4   Se nsiti vit y  A nal ysis of Pri mar y E n d p oi nt: Wei g hte d A N C O V A of A n n ualize d 
C ha n ge i n e G F R ( C K D -E PI ) fr o m Pre-treat me nt Baseli ne ( m L/ mi n/ 1. 7 3 m 2/ yr)
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 6 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -5. 2. 1   Ke y  Sec o n dar y E n d p oi nt: Li near Mi xe d Effect M o del of A n n ualize d e G F R 
( C K D-E PI) C ha n ge Sl o pe ( m L / mi n/ 1. 7 3 m 2/ yr)   – K e y  Sec o n dar y E n d p oi nt Efficac y 
P o p ulati o n
C T -5. 2. 2. 1   Se nsiti vit y  A nal ysis of Ke y Sec o n dar y E n d p oi nt: M M R M A nal ysis of e G F R 
( C K D-E PI) C ha n ge Sl o pe fr o m Baseli ne i n Ra n d o mize d Treat m e nt Peri o d   
( m L/ mi n/ 1. 7 3 m 2/ yr)
C T -5. 2. 2. 2   Se nsiti vit y  A nal ysis of Ke y Sec o n dar y E n d p oi nt: M M R M A nal ysis of e G F R 
( C K D-E PI) C ha n ge Sl o pe fr o m Baseli ne   ( m L/ mi n/ 1. 7 3 m 2/ y r)
C T -5. 2. 3   Se nsiti vit y  A nal ysis of Ke y Sec o n dar y E n d p oi nt: Li near Mi xe d M o del o f 
A n n ualize d e G F R ( C K D -E PI) C ha n ge Sl o pe   ( m L/ mi n/ 1. 7 3 m 2/ y r)
C T -5. 2. 4. 1   Se nsiti vit y  A nal ysis of Ke y Sec o n dar y E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data   ( Pr o gressi o n of Re nal Disease a n d Lac k of Efficac y  i n T ol va pta n 
Treat me nt Gr o u p as M N A R)
C T -5. 2. 4. 2   Se nsiti vit y  A nal ysis of Ke y Sec o n dar y E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data   ( Pr o gressi o n of Re nal Disease, Lac k of Efficac y , a n d Ot her A d verse 
E ve nts i n T ol va pta n Treat me nt Gr o u p as M N A R)
C T -5. 2. 5. 1   Se nsiti vit y  A nal ysis of Ke y Sec on dar y  E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data   ( Pr o gressi o n of Re nal Disease a n d Lac k of Efficac y  i n T ol va pta n 
Treat me nt Gr o u p as M N A R)
C T -5. 2. 5. 2   Se nsiti vit y  A nal ysis of Ke y Sec o n dar y E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data   ( Pr o gressi o n of Re nal Disease, Lac k of Efficac y , a n d Ot her A d verse 
E ve nts i n T ol va pta n Treat me nt Gr o u p as M N A R)
C T -6. 1   S u b gr o u p A nal ysis of Pri mar y  E n d p oi nt: Wei g hte d A N C O V A of A n n ualize d 
C ha n ge i n e G F R ( C K D -E PI ) fr o m Pre-treat me nt Baseli ne   t o P ost-treat me nt F oll o w- u p 
( m L/ mi n/ 1. 7 3 m 2/ yr)
C T -6. 2   S u b gr o u p A nal ysis of Ke y  Sec o n dar y E n d p oi nt: Li near Mi xe d Effect M o del of 
A n n ualize d e G F R ( C K D -E PI) C ha n ge Sl o pe ( m L/ mi n/ 1. 7 3 m 2/ y r)   – Ke y Sec o n dar y  
E n d p oi nt Efficac y  P o p ulati o n
C T -7. 1. 1   E xte nt of E x p os ure t o St u d y Me dicati o n   Pri mar y  Safety P o p ulati o n, D o u ble -
bli n d Treat me nt Peri o d
C T -7. 1. 2   E xte nt of E x p os ure t o St u d y  Me dicati o n   Sec o n dar y Safety P o p ulati o n, 
Si n gle - bli n d T ol va pta n Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 7 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -7. 2. 1   E xte nt of E x p os ure t o St u d y  Me dicati o n b y T otal Dail y D ose   Pri mar y Safety 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 1. 1   I nci de nce of A d verse E ve nts ( All Ca usalities)   Pri mar y  Safety P o p ulati o n, 
D o u ble- bli n d Treat me nt Peri o d
C T -8. 1. 2. 1   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class 
a n d Me d D R A Preferre d Ter m   Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt 
Peri o d
C T -8. 1. 2. 2   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d Se verit y    Pri mar y Safet y P o p ulati o n, D o u ble-bli n d 
Treat me nt Peri o d
C T -8. 1. 2. 3   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts wit h at least 5 % i n a n y  
Treat me nt Gr o u p   b y S yste m Or ga n Class a n d Me d D R A Preferre d Ter m   Sec o n dar y 
Safet y  P o p ulati o n, Si n gle- bli n d T ol va pta n Treat me nt Peri o d
C T -8. 1. 2. 4   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts wit h at least 3 % i n a n y  
Treat me nt Gr o u p   b y S yste m Or ga n Class a n d Me d D R A Preferre d Ter m   Sec o n dar y 
Safet y  P o p ulati o n, Si n gle- bli n d T ol va pta n Treat me nt Peri o d
C T -8. 1. 2. 5   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts wit h at least 2 % i n a n y  
Treat me nt Gr o u p   b y S yste m Or ga n Class a n d Me d D R A Preferre d Ter m   Sec o n dar y 
Safet y  P o p ulati o n, Si n gle- bli n d T ol va pta n Treat me nt Peri o d
C T -8. 1. 2. 6   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts wit h at least 2 % i n t he 
T ol va pta n Gr o u p a n d Greater T ha n Place b o   b y S ys te m Or ga n Class a n d Me d D R A 
Preferre d Ter m   Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -8. 1. 3. 1   I nci de nce of P ote ntiall y  Dr u g-relate d Treat me nt E mer ge nt A d verse E ve nts 
b y  S y ste m Or ga n Class a n d Me d D R A Preferre d Ter m   Pri mar y Safety P o p ulati o n, 
D o u ble- bli n d Treat me nt Peri o d
C T -8. 1. 3. 2   I nci de nce of P ote ntiall y  Dr u g-relate d Treat me nt E mer ge nt A d verse E ve nts 
b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m a n d Se verit y   Pri mary Safet y 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 1. 4. 1   I nci de nce of Deat hs D ue t o Treat me nt E mer ge nt A d verse E ve nts b y  S yste m 
Or ga n Class a n d Me d D R A Preferre d Ter m   Pri mar y  Safety P o p ulati o n, D o u ble -bli n d 
Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 8 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -8. 1. 5. 1   I nci de nce of Seri o us Treat me nt E mer ge nt A d verse E ve nts b y  S yste m Or ga n 
Class a n d Me d D R A Preferre d Ter m   Pri mar y  Safet y P o p ulati o n, D o u ble-bli n d Treat me nt 
Peri o d
C T -8. 1. 5. 2   I nci de nce of Seri o us Treat me nt E mer ge nt A d verse E ve nts b y  S yste m Or ga n 
Class, Me d D R A Pref erre d Ter m a n d Se verit y   Pri mar y Safety P o p ulati o n, D o u ble -bli n d 
Treat me nt Peri o d
C T -8. 1. 6. 1   I nci de nce of Treat me nt -E mer ge nt A d verse E ve nts Res ulti n g i n 
Disc o nti n uati o n fr o m St u d y  Me dicati o n   b y Sys te m Or ga n Class a n d Me d D R A Preferre d 
Ter m   Pri mar y  Safet y P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 1. 6. 2   I nci de nce of Treat me nt -E mer ge nt A d verse E ve nts Res ulti n g i n 
Disc o nti n uati o n fr o m St u d y  Me dicati o n   b y Sys te m Or ga n Class, Me d D R A Preferre d 
Ter m a n d Se verit y    Pri mar y Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 1. 7. 1   I nci de nce of Treat me nt - E mer ge nt A d verse E ve nts Res ulti n g i n D o w n-
Titrati o n of St u d y  Me dicati o n   b y Sys te m Or ga n Class a n d Me d D R A Preferre d Ter m   
Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T - 8. 1. 7. 2   I nci de nce of Treat me nt - E mer ge nt A d verse E ve nts Res ulti n g i n D o w n-
Titrati o n of St u d y  Me dicati o n   b y Sys te m Or ga n Class, Me d D R A Preferre d Ter m a n d 
Se verit y    Pri mar y Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 1. 8   I nci de nce of Treat me nt -E mer ge n t A d verse E ve nts Occ uri n g wit hi n 1 4 Da ys 
after Last D ose of St u d y Me dicati o n   b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m 
a n d Se verit y   Pri mar y Safet y P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 1. 9   I nci de nce of N o n -seri o us Treat me nt E mer ge nt A d verse E ve nts wit h at least 
5 % i n a n y Treat me nt Gr o u p   b y S ys te m Or ga n Class a n d Me d D R A Preferre d Ter m   
Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 1. 1 0   I nci de nce a n d Occ urre nce ( N u m ber of E ve nts) of Treat me nt E mer ge nt 
A d verse E ve nts wit h at least 5 % i n a n y Treat me nt Gr o u p   b y S ys te m Or ga n Class a n d 
Me d D R A Preferre d Ter m   Pri mar y  Safet y P o p ulati o n, D o u ble-bli n d Treat me nt Peri o d
C T -8. 2. 1   I nci de nce of A d verse E ve nts ( All Ca usalities)   Sec o n dar y  Safet y P o p ulati o n, 
Si n gle -bli n d T ol va pt a n Treat me nt Peri o d
C T -8. 2. 2. 1   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class 
a n d Me d D R A Preferre d Ter m   Sec o n dar y  Safety P o p ulati o n, Si n gle - bli n d T ol va pta n 
Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 3 9 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -8. 2. 2. 2   I nci de nce of Treat me nt E mer ge nt A d verse E v e nts b y S ys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d Se verit y    Sec o n dar y Safety P o p ulati o n, Si n gle -bli n d 
T ol va pta n Treat me nt Peri o d
C T -8. 2. 3. 1   I nci de nce of P ote ntiall y  Dr u g-relate d Treat me nt E mer ge nt A d verse E ve nts 
b y  Sys te m Or ga n Class a n d Me d D R A Preferre d Ter m   Sec o n dar y Safety P o p ulati o n, 
Si n gle - bli n d T ol va pta n Treat me nt Peri o d
C T -8. 2. 3. 2   I nci de nce of P ote ntiall y  Dr u g-relate d Treat me nt E mer ge nt A d verse E ve nts 
b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m a n d Se verit y   Sec o n dar y Safety 
P o p ulati o n , Si n gle-bli n d T ol va pta n Treat me nt Peri o d
C T -8. 2. 4. 1   I nci de nce of Deat hs D ue t o Treat me nt E mer ge nt A d verse E ve nts b y  S yste m 
Or ga n Class a n d Me d D R A Preferre d Ter m   Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d 
T ol va pta n Treat me nt Peri o d
C T - 8. 2. 5. 1   I nci de nce of Seri o us Treat me nt E mer ge nt A d verse E ve nts b y  S yste m Or ga n 
Class a n d Me d D R A Preferre d Ter m   Sec o n dar y  Safet y P o p ulati o n, Si n gle-bli n d 
T ol va pta n Treat me nt Peri o d
C T -8. 2. 5. 2   I nci de nce of Seri o us Treat me nt E mer ge nt A d verse E ve nts b y  S yste m Or ga n 
Class, Me d D R A Preferre d Ter m a n d Se verit y    Sec o n dar y Safety P o p ulati o n, Si n gle -
bli n d T ol va pta n Treat me nt Peri o d
C T -8. 2. 6. 1   I nci de nce of Treat me nt -E mer ge nt A d verse E ve nts Res ulti n g i n 
Disc o nti n uati o n fr o m St u d y  Me dicati o n   b y Sys te m Or ga n Class a n d Me d D R A Preferre d 
Ter m   Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -8. 2. 6. 2   I nci de nce of Treat me nt -E mer ge nt A d verse E ve nts Res ulti n g i n 
Disc o nti n uati o n fr o m St u d y  Me dicati o n   b y Sys te m Or ga n Class, Me d D R A Preferre d 
Ter m a n d Se verit y    Sec o n dar y Safety P o p ulati o n, Si n gle - bli n d T ol va pta n Treat me nt 
Peri o d
C T -8. 2. 9   I nci de nce of N o n -seri o us Treat me nt E mer ge nt A d verse E ve nts wit h at least 
5 % i n a n y Treat me nt Gr o u p   b y S ys te m Or ga n Class a n d Me d D R A Preferre d Ter m   
Sec o n dar y  Safet y P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -8. 2. 1 0   I nci de nce a n d Occ urre nce ( N u m ber of E ve nts) of Treat me nt E mer ge nt 
A d verse E ve nts wit h at least 5 % i n a n y Treat me nt Gr o u p   b y S ys te m Or ga n Class a n d 
Me d D R A Preferre d Ter m   Sec o n dar y  Safet y P o p ulati o n, Si n gle- bli n d T ol va pta n 
Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 0 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -8. 3. 1. 1   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d Se x   Pri mar y  Safet y P o p ulati o n, D o u ble-bli n d Treat me nt 
Peri o d
C T -8. 3. 1. 2   I nci de nce of T reat me nt E mer ge nt A d verse E ve nts by S ys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d Race Gr o u p   Pri mar y  Safety P o p ulati o n, D o u ble -bli n d 
Treat me nt Peri o d
C T -8. 3. 1. 3   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d A ge Gr o u p   Pri mar y  Safety P o p ulati o n, D o u ble -bli n d 
Treat me nt Peri o d
C T -8. 3. 1. 4   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d C o u ntr y    Pri mar y Safet y P o p ulati o n, D o u ble-bli n d 
Treat me nt Peri o d
C T -8. 3. 1. 5   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d Baseli ne e G F R   Pri mar y  Safety P o p ulati o n, D o u ble -bli n d 
Treat me nt Peri o d
C T -8. 3. 1. 6   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d T K V Stratificati o n   Pri mar y  Safety P o p ulati o n, D o u ble -
bli n d Treat me nt Peri o d
C T -8. 3. 1. 7   I nci de nce of Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, 
Me d D R A Preferre d Ter m a n d Baseli ne C K D Sta ge   Pri mar y  Safet y P o p ulati o n, D o u ble -
bli n d Treat me nt Peri o d
C T -8. 5. 1. 1   I nci de nce of He patic Fail ure, Fi br osis a n d Cirr h osis a n d Ot her Li ver 
Da ma ge -relate d C o n diti o ns   Treat me nt E mer ge nt A d verse E ve nts b y Sys te m Or ga n 
Class, Me d D R A Preferre d Ter m b y S ys te m Or ga n Class a n d Me d D R A Preferre d Ter m   
Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 5. 1. 2   I nci de nce of C h olestasis a n d Ja u n dice of He patic Ori gi n   Treat me nt 
E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m   Pri mar y 
Safet y  Po p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 5. 1. 3   I nci de nce of He patitis N o n -i nfecti o us   Treat me nt E mer ge nt A d verse E ve nts 
b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m   Pri mar y Safet y P o p ulati o n, D o u ble-
bli n d Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 1 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -8. 5. 1. 4   I nci de nce of L i ver-relate d I n vesti gati o ns, Si g ns, a n d S y m pt o ms   Treat me nt 
E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m   Pri mar y 
Safet y  P o p ulati o n, D o u ble-bli n d Treat me nt Peri o d
C T -8. 5. 1. 5   I nci de nce of L i ver-relate d C oa g ulati o n a n d Blee di n g Dist ur ba nces   
Treat me nt E mer ge nt A d verse E ve nts b y S ys te m Or ga n Class, Me d D R A Preferre d Ter m   
Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -8. 5. 1. 6   I nci de nce of S ki n Mali g na nt T u m o urs   Treat me nt E mer ge nt A d verse E ve nts 
b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m   Pri mar y  Safet y P o p ulati o n, D o u ble-
bli n d Treat me nt Peri o d
C T -8. 5. 1. 7   I nci de nce of S ki n T u m o urs of U ns pecifie d Mali g na nc y  ( S M Q)   Treat me nt 
E mer ge nt A d verse E ve nts b y  Sys te m Or ga n Class, Me d D R A Preferre d Ter m   Pri mar y
Safet y  P o p ulati o n, D o u ble-bli n d Treat me nt Peri o d
C T -8. 5. 1. 8   I nci de nce of Gla uc o ma   Treat me nt E mer ge nt A d verse E ve nts b y  Sys te m 
Or ga n Class, Me d D R A Preferre d Ter m   Pri mar y  Safet y P o p ulati o n, D o u ble-bli n d 
Treat me nt Peri o d
C T -8. 6. 1   I nci de nce of Treat me nt -e mer ge nt A d verse E ve nt a n d Its A nalys es   A Es wit h 
T L V I nci de nce > = 1 % a n d At Least 0. 5 % > place b o or T L V I nci de nce < 1 % a n d 2 ti mes 
> place b o or Si g nifica nt P -val ue i n Fis her's E xact Test   Pri mar y  Safety P o p ulati o n, 
D o u ble- bli n d Treat me nt Peri o d
C T -9. 1. 1   L isti n g of Deat hs
C T -9. 1. 2   L isti n g of Seri o us A d verse E ve nts
C T -9. 1. 3   L isti n g of A d verse E ve nts Res ulti n g i n Disc o nti n uati o ns of St u d y Me dicati o n
C T -1 0. 1   Criteria f or I de ntif y i n g La b orat or y Val ues of P ote ntial Cli nical Si g nifica nce
C T -1 0. 2. 2. 1   L isti n g of La b orat or y Test Val ues wit h P ote ntial Cli nical Si g nifica nce by 
S u bject   Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -1 0. 2. 2. 2   L isti n g of La b orat or y Test Val ues wit h P ote ntial Cli nical Si g nifica nce by 
Test   Pri mar y  Safet y P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -1 0. 2. 2. 3   L isti n g of La b orat or y A b n or malities t hat Si g nal P ote ntial Dr u g-i n d uce d 
Li ver I nj ur y    Pri mar y Safet y P o p ulati o n, D o u ble-bli n d Treat me nt Peri o d
C T -1 0. 2. 3. 1   I nci de nce of La b orat or y  Test Val ues wit h P ote ntial Cli nical Si g nifica nce   
Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 2 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -1 0. 2. 3. 2   I nci de nce of La b orat or y  A b n or malities t hat Si g nal P ote ntial Dr u g-i n d uce d 
Li ver I nj ur y    Pri mar y Safet y P o p ulati o n, D o u ble-bli n d Treat me nt Peri o d
C T -1 0. 2. 4. 1   Mea n C ha n ge Fr o m Baseli ne i n La b orat or y  Test Val ues: Ser u m C he mistr y   
Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -1 0. 2. 4. 2   Mea n C ha n ge Fr o m Baseli ne i n La b orat or y  Test Val ues: He mat ol o g y   
Pri mar y  Safety P o p ulati o n , D o u ble-bli n d Treat me nt Peri o d
C T -1 0. 2. 4. 3   Mea n C ha n ge Fr o m Baseli ne i n La b orat or y  Test Val ues: Uri nal ysis   
Pri mar y  Safety P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -1 0. 3. 2. 1   L isti n g of La b orat or y Test Val ues wit h P ote ntial Cli nical Si g nifica nce b y  
S u bject   Sec o n dar y  Safet y P o p ulati o n, Si n gle-bli n d T ol va pta n Treat me nt Peri o d
C T -1 0. 3. 2. 2   L isti n g of La b orat or y Test Val ues wit h P ote ntial Cli nical Si g nifica nce by 
Test   Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T - 1 0. 3. 2. 3   L isti n g of La b orat or y A b n or malities t hat Si g nal P ote ntial Dr u g-i n d uce d 
Li ver I nj ur y    Sec o n dar y Safet y P o p ulati o n, Si n gle- bli n d T ol va pta n Treat me nt Peri o d
C T -1 0. 3. 3. 1   I nci de nce of La b orat or y  Test Val ues wit h P ote ntial Cli nical Si g nifica nce   
Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -1 0. 3. 3. 2   I nci de nce of La b orat or y  A b n or malities t hat Si g nal P ote ntial Dr u g-i n d uce d 
Li ver I nj ur y    Sec o n dar y Safet y P o p ulati o n, Si n gle- bli n d T ol va pta n Treat me nt Peri o d
C T -1 0. 3. 4. 1   Mea n C ha n ge Fr o m Baseli ne i n La b orat or y  Test Val ues: Ser u m C he mistr y   
Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -1 0. 3. 4. 2   Mea n C ha n ge Fr o m Baseli ne i n La b orat or y  Test Val ues: He mat ol o g y   
Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -1 0. 3. 4. 3   Mea n C ha n ge Fr o m Baseli ne i n La b orat or y  Test Val ues: Uri nal ysis   
Sec o n dar y  Safety P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -1 1. 1   Criteria f or I de ntif y i n g Vital Si g ns wit h P ote ntial Cli nical Si g nifica nce
C T -1 1. 2. 1   L isti n g of Vital Si g ns wit h P ote ntial Cli nical Rele va nce   Pri mar y Safety 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -1 1. 2. 2   I nci de nce of Vital Si g ns wit h P ote ntial Cli nical Rele va nce   Pri mar y  Safety 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
C T -1 1. 2. 3   Mea n C ha n ge fr o m Baseli ne i n Vital Si g ns Para meters   Pri mar y  Safety 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 3 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7C T -1 1. 3. 1   L isti n g of Vital Si g ns wit h P ote ntial Cli nical Rele va nce   Sec o n dar y Safety 
P o p ulati o n, Si n gle -bli n d T ol va p ta n Treat me nt Peri o d
C T -1 1. 3. 2   I nci de nce of Vital Si g ns wit h P ote ntial Cli nical Rele va nce   Sec o n dar y  Safety 
P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -1 1. 3. 3   Mea n C ha n ge fr o m Baseli ne i n Vital Si g ns Para meters   Sec o n dar y  Safety 
P o p ulati o n, Si n gle -bli n d T ol va pta n Treat me nt Peri o d
C T -1 2   S u m mar y  of P K D O utc o me - Ra n d o mize d, D o u ble -bli n d Treat me nt Peri o d
C T -1 3. 1. 1   A nal ys is of Pri mar y E n d p oi nt b y Site: Wei g hte d A N C O V A of A n n ualize d 
C ha n ge i n e G F R ( C K D -E PI ) fr o m Pre-treat me nt Baseli ne   t o P ost -treat me nt F oll o w- u p 
( m L/ mi n/ 1. 7 3 m 2/ yr)
C T -1 3. 1. 2   A nal ys is of Pri mar y E n d p oi nt b y C o u ntr y: Wei g hte d A N C O V A of 
A n n ualize d C ha n ge i n e G F R ( C K D -E PI) fr o m Pre -treat me nt Baseli ne   t o P ost-treat me nt 
F oll o w -u p ( m L/ mi n/ 1. 7 3 m 2/ y r)
C T -1 4. 1   E x pl orat or y  A nal ysis of Pri mar y E n d p oi nt: Wei g hte d A N C O V A Base d o n 
M o dal D ose of A n n ualize d C ha n ge i n e G F R ( C K D -E PI) fr o m Pre -treat me nt Baseli ne   t o 
P ost -treat me nt F oll o w-u p ( m L / mi n/ 1. 7 3 m 2/ yr) - Pri mar y  E n d p oi nt Efficac y P o p ulati o n
C T -1 4. 2   E x pl orat or y  Anal y sis of Ke y Sec o n dar y E n d p oi nt: Li near Mi xe d Effect M o del 
Base d o n M o dal D ose of A n n ualize d e G F R ( C K D -E PI) C ha n ge Sl o pe ( m L/ mi n/ 1. 7 3 
m 2/ y r)   – K e y  Sec o n dar y E n d p oi nt Efficac y P o p ulati o n
C T -1 4. 3. 1   E x pl orat or y  A nal ysis of Ti me t o M ulti ple E ve nt A nalys is of C O M P O SIT E 
O F 6 A D P K D O U T C O M E S
C T -1 4. 3. 2   E x pl orat or y  A nal ysis of Ti me t o M ulti ple E ve nt A nalys is of G R O S S 
H E M A T U RI A
C T -1 4. 3. 3   E x pl orat or y  A nal ysis of Ti me t o M ulti ple E ve nt A nalys is of KI D N E Y P AI N
C T -1 4. 3. 4   E x pl orat or y  A nal ysis of Ti me t o M ulti ple E ve nt A nal ys is of U RIN A R Y 
T R A C T I N F E C TI O N
C T -1 4. 3. 5   E x pl orat or y  A nal ysis of Ti me t o First E ve nt A nalys is of C O M P O SIT E O F 6 
A D P K D O U T C O M E S
C T -1 4. 3. 6   E x pl orat or y  A nal ysis of Ti me t o First E ve nt A nalys is of G R O S S 
H E M A T U RI A
C T -1 4. 3. 7   E x pl orat or y  A nal ysis of Ti me t o First E ve nt A nalys is of KI D N E Y P AI N
C T -1 4. 3. 8   E x pl orat or y  A nal ysis of Ti me t o First E ve nt A nalys is of U RI N A R Y T R A C T 
I NF E C TI O N
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 4 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7A p pe n di x 4 T a ble of C o nte nts f or Cli nic al Fi g ures
Fi g ure 1. 1 A n n ualize d C ha n ge i n e G F R ( C K D-E PI ) fr o m Pre-treat me nt Baseli ne t o P ost-
treat me nt F oll o w-u p Pri mar y  E n d p oi nt Efficac y P o p ulati o n
Fi g ure 1. 2 A n n ualize d C ha n ge i n e G F R ( C K D -E PI ) fr o m Pre-treat me nt Baseli ne t o P ost-
treat me nt F oll o w-u p Pri mar y  E n d p oi nt Efficac y P o p ulati o n ( A d diti o nal Se nsiti vit y 
A nal y ses)
Fi g ure 2. 1 Li near Mi xe d Effect M o del of A n n ualize d e G F R ( C K D -E PI) C ha n ge Sl o pe 
K e y  Sec o n dar y E n d p oi nt Efficac y P o p ulati o n
Fi g ure 2. 2. 1 e G F R ( C K D -E PI) Val ues a n d T heir Re gressi o n Li nes fr o m L i near Mi xe d 
Effect M o del Ke y  Sec o n dar y E n d p oi nt Efficac y P o p ulati o n
Fi g ure 2. 2. 2 e G F R ( C K D -E PI) Val ues a n d T heir Re gressi o n Li nes fr o m L i near Mi xe d 
Effect M o del Ke y  Sec o n dar y E n d p oi nt P o p ulati o n, Incl u di n g Data C ollecte d D uri n g t he 
P ost -disc o nti n uati o n F oll o w - u p
Fi g ure 3. 1 Se nsiti vit y A nal ysis: Sl o pe C o m paris o n Base d o n M M R M A nal ysis of e G F R 
( C K D-E PI) C ha n ge fr o m Baseli ne Ke y  Sec o n dar y E n d p oi nt P o p ulati o n
Fi g ure 3. 2 Se nsiti vit y A nal y sis: M M R M A nal ysis of e G F R ( C K D-E PI) C ha n ge fr o m 
Baseli ne Ke y  Sec o n dar y E n d p oi nt P o p ulati o n
Fi g ure 4. 1 Se nsiti vit y  A nal ysis of Ke y Sec o n dar y E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data ( Pr o gressi o n of Re nal Disease a n d Lac k of Efficac y  i n T ol va pta n 
Treat me nt Gr o u p as M N A R), Ke y  Sec o n dar y E n d p oi nt Efficac y P o p ulati o n
Fi g ure 4. 2 Se nsiti vit y  A nal ysis of K e y  Sec o n dar y E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data ( Pr o gressi o n of Re nal Disease, Lac k of Efficac y , a n d Ot her A d verse E ve nts 
i n T ol va pta n Treat me nt Gr o u p as M N A R), Ke y Sec o n dar y E n d p oi nt Efficac y P o p ulati o n
Fi g ure 4. 3 Se nsiti vit y  A nal ysis of Ke y Sec o n dar y  E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data ( Pr o gressi o n of Re nal Disease a n d Lac k of Efficac y  i n T ol va pta n 
Treat me nt Gr o u p as M N A R), Ke y  Sec o n dar y E n d p oi nt Efficac y P o p ulati o n, Incl u di n g 
Data fr o m S u bjects W h o Disc o nti n ue I M P
Fi g ure 4. 4 Se n siti vit y A nal ysis of Ke y Sec o n dar y E n d p oi nt: M ulti ple Im p utati o n f or 
Missi n g Data ( Pr o gressi o n of Re nal Disease, Lac k of Efficac y , a n d Ot her A d verse E ve nts 
i n T ol va pta n Treat me nt Gr o u p as M N A R), Ke y Sec o n dar y E n d p oi nt Efficac y P o p ulati o n, 
I ncl u di n g Data fro m S u bjects W h o Disc o nti n ue I M P
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 5 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7Fi g ure 5. 1 A n n ualize d C ha n ge i n e G F R ( C K D -E PI ) fr o m Pre-treat me nt Baseli ne t o P ost-
treat me nt F oll o w-u p b y  S u b gr o u p Pri mar y E n d p oi nt Efficac y P o p ulati o n
Fi g ure 5. 2 Li near Mi xe d Effect M o del of A n n ualize d e G F R ( C K D -E PI) C ha n ge Sl o pe b y 
S u b gr o u p Ke y  Sec o n dar y E n d p oi nt Efficac y P o p ulati o n
Fi g ure 6. 1 Treat me nt Differe nce i n A n n ualize d C ha n ge i n e G F R ( C K D -E PI ) fr o m Pre-
treat me nt Baseli ne t o P ost-treat me nt F oll o w-u p b y Site, Pri mar y  E n d p oi nt Efficac y 
P o p ulati o n
Fi g ure 6. 2 Tr eat me nt Differe nce i n A n n ualize d C ha n ge i n e G F R ( C K D- E PI ) fr o m Pre-
treat me nt Baseli ne t o P ost-treat me nt F oll o w-u p b y C o u ntr y , Pri mar y E n d p oi nt Efficac y 
P o p ulati o n
Fi g ure 7 . 1 Mea n of Esti mate d A n n ualize d e G F R C ha n ge f or S u bjects 
C o m plete d/ Disc o nti n ue d fr o m Treat me nt, Pri mar y  E n d p oi nt Efficac y P o p ulati o n
Fi g ure 7 . 2 Mea n of Esti mate d A n n ualize d e G F R C ha n ge by R eas o n f or Disc o nti n uati o n 
fr o m Treat me nt, Pri mar y E n d p oi nt Efficac y P o p ulati o n
Fi g ure 8 . 1 Mea n C ha n ge fr o m Baseli ne i n e G F R ( C K D- E PI) f or Dr o p o uts - T ol va pta n, 
K e y  Sec o n dar y E n d p oi nt P o p ulati o n
Fi g ure 8 . 2 Mea n C ha n ge fr o m Baseli ne i n e G F R ( C K D- E PI) f or Dr o p o uts - Place b o, Ke y  
Sec o n dar y  E n d p oi nt P o p ulati o n
Fi g ure 9 . 1 Ka pla n-Meier C ur ves of Ti me t o Disc o nti n uati o n of St u d y  All Ra n d o mize d 
S u bjects
Fi g u re 9 . 2 Ka pla n-Meier C ur ves of Ti me t o Disc o nti n uati o n of I M P Pri mar y  Safet y 
P o p ulati o n
Fi g ure 1 0 . 1 I nci de nce of Treat me nt E mer ge nt A d verse E ve nts wit h at least 5 % i n a n y 
Treat me nt Gr o u p Pri mar y  Safet y P o p ulati o n, D o u ble-bli n d Treat me nt Peri o d
Fi g ure 1 0 . 2. 1 Ka pla n-Meier C ur ves of Ti me t o T E A E i n L i ver Pri mar y Safet y 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
Fi g ure 1 0 . 2. 2 Ka pla n-Meier C ur ves of Ti me t o T E A E i n S ki n Ne o plas ms Pri mar y  Safety 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
Fi g ure 1 1 . 1 Ka pla n-Meier C ur ves of Ti me t o A L T > 3 x U L N Pri mar y  Safet y P o p ulati o n, 
D o u ble- bli n d Treat me nt Peri o d
Fi g ure 1 1. 2. 1  Ka pla n -Meier C ur ves of Ti me fr o m Pea k A L T t o N or mal ( < 1 x U L N)  
Pri mar y  Safety P o p ulati o n, A dj u dicate d S u bjects
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 6 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7Fi g ure 1 1. 2. 2  Ka pla n -Meier C ur ves of Ti m e fr o m Pea k A L T t o N or mal ( < 1 x U L N) 
Base d o n Disc o nti n uati o n Stat us i n T ol va pta n Gr o u p  Pri mar y  Safety P o p ulati o n, 
A dj u dicate d S u bjects
Fi g ure 1 2. 1  Pea k Bilir u bi n/ U L N Rati o vers us Pea k A L T/ U L N Rati o  Pri mar y  Safety 
P o p ulati o n, D o u ble -bli n d Treat me nt Peri o d
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 7 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 8 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7 
 
 
  
 
 
 
 
 
                                                                       
                                                                              
                                                  
                                                                                                                       
                                                                                                                                
                                                             
                                                                                                   
                                                                                                                                
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 4 9 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7T a bl e 2
2 1 0 A N O V A T a bl e of C h a n g e fr o m B as eli n e o m e G F R F oll o w -u p O bs er v ati o ns
P ost Tr e at m e nt F oll o w -u p Visits 1, 2, a n d 3
                                            S o urc e D F         S S         M S F- v al u e P- v al u e                                             
                                            ------------------------------------------------------------                                             
                                            B et w e e n   9    1 7 0 9. 7 5   1 8 9. 9 7      1 4. 8 1  <. 0 0 0 1                                              
                                            Wit hi n 1 5     1 9 2. 3 6     1 2. 8 2                                                               
                             C orr ect e d T ot al 2 4    1 9 0 2. 1 0                                                                        
Beca use t he mea n s u m s q uare of wit hi n -s u bject err or ( 1 2. 8 2) i n st u d y 2 1 0 is o nl y ~ 6. 7 % 
of t he mea n s u m s q uare of bet wee n -s u bject err or ( 1 8 9. 9 7), we ma y c o ncl u de t hat t he 
i ncrease of e G F R o bser vati o ns ( use of m ore t ha n o ne o bser vati o n) d oes n ot re d uce t he 
varia nce of t heir a vera ge m uc h, si nce i ncrease d n u m bers of o bser vati o ns o nl y  re d uce t he 
wit hi n - varia nce c o m p o ne nt i n t heir a vera ge, a n d t here is little wit hi n-s u bject variati o n t o 
be f urt her re d uce d.   
 
  Si nce t he 2 1 0 e G F R data use d f or t his bli n de d sa m ple size re-calc ulati o n 
are base d o n Rate Bla n k ser u m creati ni ne  
, t his fact ma y raise t he q uesti o n of w het her t he wit hi n-
s u bject err ors of t hese t w o ki n ds of ser u m creati ni ne are ver y differe nt or n ot.  It is li kel y 
t hat Rate Bla n k ser u m creati ni ne is m ore sta ble wit h less wit hi n-s u bject variati o n.  
I n dee d, t his was c o nsi dere d a n a d va nta ge of t he Rate Bla n k met h o d w he n o ur ce ntral la b 
ve n d o r, C o va nce, rec o m me n de d it t o us.  T h us, it is n ot k n o w n w het her t he s mall wit hi n-
s u bject err or in 2 1 0 is ca use d b y  Rate Bla n k data or is act ually occ urri n g i n 2 1 0 e G F R 
data.  Beca use of t his, t here are n o gr o u n ds f or ma ki n g a n y c ha n ges t o t he n u m ber of 
e G F R o bser vati o n at pre -treat me nt baseli ne a n d p ost-treat me nt f oll o w-u p visits, u nless 
2 1 0 e G F R dat a base d o n E nz ymatic ser u m creati ni ne are a vaila ble.  Base d o n t he c urre nt 
cli nical o perati o n pla n, E nz ymatic ser u m creati ni ne data are o nl y a vaila ble w he n s u bjects 
fi nis h t heir 1 2- m o nt h visits as well as t heir p ost -treat me nt f oll o w- u p visits (f or b ot h 
c om pleter a n d earl y wit h dre w s u bject), si nce batc he d a nal ys is o n fr oze n bl o o d sa m ples of 
all visits w o ul d o nl y be d o ne after t hat.  T h us, m ore a p pr o priate a nal ysis t o deter mi ne t he 
n u m ber of e G F R o bser vati o ns at pre -treat me nt baseli ne a n d p ost-treat me nt f ollo w- u p 
visits ca n o nl y  be pr o vi de d after m ore s u bjects c o m plete t he st u d y.   
Q uesti o n 2:  T he differe nces bet wee n t he o bser ve d v ari a nces a n d t he v ari a nces use d 
i n t he s a m ple size c alc ul ati o n 
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 5 0 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7T o a d dress t his q uesti o n, t he m ost strai g htf or war d wa y  is t o l o ok at t he varia nce of t he 
a vera ge e G F R c ha n ge fr o m baseli ne at p ost -treat me nt f oll o w-u p visits, w hic h is gi ve n i n 
t he f oll o wi n g c ha n ge fr o m baseli ne b y-visit ta ble:
T a bl e 3
N ote t hat t he S D of a vera ge c ha n ge fr o m baseli ne at F oll o w- u p is 8. 0 0, w hic h is greater 
t ha n t he S D use d i n t he sa m ple size calc ulati o n ( 5. 7 3, e q ual t o t he s q uare r o ot of 3 2. 8).  
H o we ver, o ut of t he 1 1 s u bjects i n t he f oll o w- u p visit, o nl y  o ne is a c o m pleter a n d t he 
ot her 1 0 are earl y  dr o p o uts.  T h us, t he varia nce at t he f oll o w-u p visit ma y  be i nflate d b y 
t he dr o p o ut s u bjects.  I n a d diti o n, f or visits wit h lar ge a m o u nt of s u bjects, sa y, visits fr o m 
M o nt h 1 t o M o nt h 7, w here s u bject n u m bers ra n ge d fr o m  6 0 t o m ore t ha n 2 0 0, t he                                              C h a n g e  f r o m  B a s e l i n e  i n  R e n a l  F u n c t i o n  ( C K D - E P I ) ,  B l i n d e d                                                
                                                                                                                             
                                             _ _ _ _ _ _ _ _ _ _       e G F R  V a l u e s _ _ _ _ _ _ _ _ _ _  _ _ _         C h a n g e  f r o m  B a s e l i n e _ _ _                          
                        V i s i t                    N    M e a n     M e d      S D     M i n     M a x     N    M e a n     M e d      S D     M i n     M a x                          
                        - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -                          
                                                                                                                                                     
                        B a s e l i n e               3 4 0   4 3 . 2 1   4 1 . 9 2   1 1 . 4 5   2 4 . 4 3   6 7 . 8 7                                                                  
                                                                                                                                                     
             T o l v a p t a n  T i t r a t i o n    3 4 1   3 9 . 6 5   3 8 . 9 1   1 0 . 8 1   2 0 . 0 2   6 9 . 6 0   3 4 1   - 3 . 6 5   - 3 . 3 7    3 . 9 7  - 2 4 . 9 4   1 3 . 1 8                          
                                                                                                                                                     
                        T o l v a p t a n  R u n - i n  D a y   3 2 1   3 9 . 9 7   3 8 . 2 8   1 1 . 2 1   2 0 . 1 8   7 4 . 7 9   3 2 1   - 3 . 2 1   - 3 . 2 0    4 . 2 2  - 2 0 . 9 2   1 5 . 5 0                          
                                                                                                                                                     
                        T o l v a p t a n  r u n - i n  D a y   3 3 4   3 9 . 8 2   3 8 . 4 6   1 0 . 9 7   1 8 . 9 0   8 2 . 3 6   3 3 4   - 3 . 4 0   - 3 . 4 1    4 . 6 3  - 2 3 . 6 7   1 6 . 9 8                          
                                                                                                                                                     
                        M o n t h  1                2 7 8   4 0 . 9 8   3 9 . 2 1   1 1 . 4 8   2 1 . 7 9   8 4 . 3 5   2 7 8   - 2 . 0 8   - 2 . 1 7    4 . 7 3  - 2 1 . 8 1   2 2 . 0 2                          
                                                                                                                                                     
                        M o n t h  2                2 2 0   4 0 . 0 0   3 9 . 2 1   1 1 . 6 0   2 0 . 6 6   8 1 . 9 5   2 2 0   - 2 . 2 7   - 2 . 2 3    4 . 9 1  - 2 4 . 4 6   1 7 . 1 8                          
                                                                                                                                                     
                        M o n t h  3                1 8 3   4 0 . 2 2   3 7 . 2 7   1 2 . 4 8   2 1 . 5 6   7 5 . 1 7   1 8 3   - 1 . 2 4   - 1 . 9 3    5 . 4 7  - 1 9 . 7 2   1 8 . 6 6                          
                                                                                                                                              
                        M o n t h  4                1 3 3   3 9 . 2 1   3 6 . 9 0   1 1 . 7 3   2 1 . 0 5   7 4 . 6 5   1 3 3   - 1 . 9 8   - 2 . 3 0    4 . 5 8  - 1 8 . 1 4   1 2 . 3 1                          
                                                                                                                                                     
                        M o n t h  5                 9 8   3 8 . 5 5   3 6 . 0 5   1 2 . 3 0   2 0 . 7 1   7 3 . 6 2    9 8   - 2 . 0 0   - 2 . 3 5    5 . 3 2  - 1 8 . 1 4   1 2 . 8 3                          
                                                                                                                                                     
                        M o n t h  6                 7 5   3 9 . 1 9   3 8 . 6 7   1 1 . 6 9   2 0 . 1 7   7 2 . 2 1    7 5   - 1 . 0 5   - 1 . 3 3    5 . 1 0  - 1 2 . 5 9   1 3 . 8 2                          
                                                                                                                                                 
                        M o n t h  7                 6 0   4 0 . 5 6   3 8 . 9 1   1 2 . 9 3   2 3 . 0 1   9 3 . 8 3    6 0   - 0 . 9 2   - 1 . 7 6    5 . 7 8  - 1 2 . 8 0   2 9 . 0 6                          
                                                                                                                                                     
                        M o n t h  8                 3 3   3 9 . 9 8   3 7 . 1 6   1 4 . 6 6   2 0 . 8 9   9 3 . 8 3    3 3   - 0 . 9 8   - 2 . 2 0    6 . 8 0   - 8 . 9 3   2 9 . 0 6                          
                                                                                                                                                     
                        M o n t h  9                 1 4   3 9 . 0 2   3 5 . 9 5   1 6 . 2 3   2 0 . 8 3   7 8 . 0 1    1 4   - 2 . 0 8   - 2 . 1 3    7 . 3 1  - 1 4 . 5 8   1 6 . 3 7                          
                                                                                                                                                     
                        M o n t h  1 0                1 0   3 9 . 3 8   3 9 . 3 1   1 2 . 9 7   2 3 . 5 0   6 1 . 2 1    1 0   - 5 . 0 0   - 4 . 2 7    4 . 4 6  - 1 4 . 3 6   - 0 . 4 1                          
                                                                                                                                                     
                        M o n t h  1 1                 1   6 1 . 2 1   6 1 . 2 1          6 1 . 2 1   6 1 . 2 1     1   - 0 . 4 3   - 0 . 4 3          - 0 . 4 3   - 0 . 4 3                          
                                                                                                                                                     
                        M o n t h  1 2                 1   6 8 . 6 8   6 8 . 6 8          6 8 . 6 8   6 8 . 6 8     1    7 . 0 4    7 . 0 4           7 . 0 4    7 . 0 4                          
                                                                                                                                                     
                        E n d  o f  T r e a t m e n t        1 0   4 7 . 9 0   4 5 . 9 1   1 7 . 0 9   1 8 . 6 8   8 1 . 9 5    1 0    1 . 1 9    1 . 8 7    9 . 5 4  - 1 5 . 6 5   1 7 . 1 8                          
                                                                                                                                                     
                        F o l l o w - u p  D a y  7         1 1   4 6 . 1 6   3 6 . 1 3   1 7 . 1 5   2 9 . 9 5   8 1 . 9 5    1 1    0 . 5 5   - 0 . 3 2    7 . 7 3   - 8 . 0 7   1 7 . 1 8                       
                                                                                                                                                     
                        F o l l o w - u p  D a y  1 4         7   4 5 . 8 8   3 8 . 9 4   1 7 . 5 5   3 2 . 6 0   8 1 . 9 5     7    1 . 0 6   - 0 . 6 0    7 . 6 9   - 5 . 2 0   1 7 . 1 8                          
                                                                                                                                                     
                        F o l l o w - u p  D a y  2 1         7   5 1 . 7 2   4 6 . 7 0   2 1 . 7 4   2 9 . 6 7   9 4 . 4 9     7    3 . 3 0   - 0 . 4 3   1 2 . 3 6   - 8 . 8 3   2 9 . 7 2                          
                                                                                                                                                     
                F o l l o w - u p  A v e r a g e       1 1   4 6 . 1 6   3 7 . 1 2   1 7 . 1 9   2 9 . 9 5   8 6 . 1 3    1 1    0 . 5 6   - 0 . 3 2    8 . 0 0   - 6 . 7 4   2 1 . 3 6                          
Pr ot oc ol 1 5 6 -1 3 -2 1 0
Statistical A nal ysis Pla n 5 1 of 5 1 Versi o n Date: 0 3/ 3 1/ 2 0 1 7varia nces of t hese visits are all less t ha n 6.  T his raises t he p ossi bilit y  t hat, w he n we ha ve 
e n o u g h s u bjects i n t he f oll o w -u p visits s o t hat t he y are n ot d o mi na nt b y earl y dr o p o uts, 
t he S D of t he a vera ge c ha n ge fr o m baseli ne at f oll ow- u p ma y  als o be ar o u n d 6.  If t his is 
t he case, t he trial w o ul d be well p o were d.  E ve n w he n t he S D raise d u p t o 6. 5, t he trial 
w o ul d still ha ve at least 8 0 % p o wer.  Beca use of t his, wit h t he li mit of t he c urre nt data f or 
t his bli n de d sa m ple size re-calc ulati o n e xercise, n o c o ncl usi o n ca n be ma de at t his ti me 
f or t he c o m paris o n bet wee n t he o bser ve d varia nces a n d t he varia nces use d i n t he sa m ple 
size calc ulati o n.
T h us, t his bli n de d sa m ple size re -esti mati o n faile d t o pr o vi de a n y rec o m me n dati o ns t o its 
o bject i ves.  T he reas o n f or faili n g t he first q uesti o n is beca use, w he n we desi g ne d t he 
pr ot oc ol, it was pla n ne d t o use e G F R deri ve d fr o m Rate Bla n k ser u m creati ni ne, si nce 
t his was rec o m me n de d b y o ur ce ntral la b ve n d or, C o va nce.  H o we ver, i n a Steeri n g 
C o m mitte e meeti n g w he n t he trial was u n der patie nt e nr oll me nt, t he C o m mittee Me m bers 
t ol d us t he y preferre d t he E nz ymatic ser u m creati ni ne.  T he y  belie ve d it is t he g ol de n 
sta n dar d i n deri vi n g e G F R.  Beca use of t his, it was deci de d t hat e G F R deri ve d fr o m Rate 
Bla n k ser u m creati ni ne w o ul d be use d o nl y f or patie nt cli nical m o nit ori n g, a n d t he e G F R 
base d o n E nz y matic ser u m creati ni ne o btai ne d fr o m batc he d a nal y sis o n fr oze n bl o o d 
sa m ples of all visits w o ul d be use d i n efficac y a nal yses.  T his c ha n ge i n cli nical o perati o n 
le d t o t he miss of t he first q uesti o n i n t his bli n de d sa m ple size re-esti mati o n e xercise.  
T h e reas o n f or miss i n g of t he sec o n d o bjecti ve i n t his bli n de d sa m ple size re -esti mati o n 
e xercise is t hat, w he n we desi g ne d t he pr ot oc ol, we w o ul d li ke t o ma ke s ure t he sa m ple 
size re-esti mati o n w o ul d be d o ne bef ore half of t he pla n ne d s u bjects were ra n d o mize d.  
Ha d we s pecifie d t o c o n d uct t he bli n de d sa m ple size re -esti mati o n at a ti me w he n 6 0 0 -
7 0 0 s u bjects were ra n d o mize d t o t he trial, or w he n 4 0 - 5 0 s u bject s c o m plete d t heir 1 2-
m o nt h p ost -treat me nt f oll o w-u p, w hic h e ver ca me later, we s h o ul d n ot ha ve pr o ble m t o 
a ns wer t he sec o n d q uesti o n. 
Ot s u k a P h ar m a c e uti c al D e v el o p m e nt & C o m m er ci ali z ati o n, I n c.
T hi s p a g e i s a m a nif e st ati o n of a n el e ctr o ni c all y c a pt ur e d si g n at ur e
                                                                                                                                
SI G N A T U R E PA G E
D oc u me nt N a me :
D oc u me nt N u m ber :
D oc u me nt Versi o n :
Si g n e d b y Me a ni n g of Si g n at ureSer ver D ate
(d d -M M M -y y y y H H : m m ‘ G M T’ Z)O P C- 4 1 0 6 1
S A P 1 5 6- 1 3- 2 1 0 Versi o n 6
0 0 0 1 2 6 4 7 4 5
2. 0
Bi ostatistics A p pr o val 0 5- A pr- 2 0 1 7 2 1: 1 4 G M T + 0 0
Cli nical A p pr o val 0 6- A pr- 2 0 1 7 1 5: 0 7 G M T + 0 0